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Abstract 
The Golgi apparatus is the main transportation and sorting organelle system for proteins 
entering the secretory pathway. It is involved in the modification of N-linked glycans, and it 
is the site for several types of O-linked glycosylation. One such mechanism is the synthesis of 
glycosaminoglycans (GAGs), which are attached to acceptor protein cores at specific 
glycosylation sites. The resulting proteoglycan (PG) can have multiple GAGs of various types 
and lengths. These GAGs are heavily sulphated in the Golgi apparatus by the universal 
sulphate donor 3'-phosphoadenosine 5'-phosphosulphate (PAPS), which is transported into the 
Golgi lumen by the Golgi transmembrane proteins 3'-phosphoadenosine 5'-phosphosulphate 
transporter 1 (PAPST1) and 2. Glycan moieties have earlier been shown to work as sorting 
signals in polarized epithelial cells, and influences whether a protein core is destined for the 
apical or basolateral side of the epithelium. In this thesis, we have studied changes in the 
Golgi morphology in Madin-Darby canine kidney (MDCK) cells as a result of chemically 
induced DNA damage, and how such morphological change affects synthesis and sorting of 
sulphated PGs in the cell line. Morphological studies were carried out using fluorescent 
confocal imaging of MDCK II cells expressing the Golgi transmembrane PAPST1 protein 
with a GFP tag in the presence of the DNA damaging agents doxorubicin (Doxo) or 
Camptothecin (CPT). The results show an increase in relative Golgi area in MDCK II cells 
post treatment with Doxo or CPT. 
Synthesis and secretion studies were carried out using metabolic labeling by incubating filter-
grown MDCK II cells with 35S-sulphate. In these studies we observed possible reduction in 
sulphated macromolecules in the apical medium, the basolateral medium and the cell lysate. 
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1 Introduction 
1.1 Golgi apparatus form and function 
Proteins that pass through the secretory pathway will pass through the Golgi apparatus and 
either be integrated in the plasma membrane, secreted or transported to endosomes or 
lysosomes. The secretory pathway originates in the endoplasmic reticulum (ER) where the 
proteins are synthesized. After completion of the polypeptide constituting the protein core, the 
proteins receive variable post-translational modifications (PTMs), such as glycosylation, as 
they move along the pathway. Several of these proteins are important for the cell’s structure 
and function, and as such, changes in their synthesis and modification can affect normal cell 
structure and function. Further, these changes can potentially lead to a transformation of 
normal cells into cancer cells. Changes in the Golgi apparatus structure and (biochemical) 
environment have been observed in cancer cells (Kellokumpu et al. 2002; Li & Wang 1989; 
Schulenberg et al. 2003). It is therefore interesting to study the connection between DNA 
damage that often leads to cancer and the Golgi apparatus structure and function.  
DNA damage can result in changes to the final gene products and the regulation of their 
synthesis and function. This can further lead to changes in the cells form and functions, 
including changes in the Golgi apparatus structure. It is of interest whether these changes 
have an effect on proteoglycan (PG) synthesis. Further, more research is needed on whether 
certain changes to the form and function of the Golgi apparatus could act as a mediator 
between DNA damage and cancer development. For example, changes in the glycosylation of 
epidermal growth factor receptors (EGF-receptors), cadherins and other important proteins 
have been observed to lead to transformation of cells (Przybylo et al. 2002; Lin et al. 2015). 
1.1.1 Proteins path through the secretory pathway 
Secretory proteins usually have an N-terminal signal sequence that is recognized by a signal 
recognition particle (SRP) in the cytoplasm. This signal is recognized as soon as it is 
translated from the ribosome and causes the translation to halt until the SRP-ribosome 
complex binds to an SRP receptor in the ER membrane. This causes the release of the SRP 
and the ribosome recruits additional ER membrane proteins to help facilitate the translation 
and translocation through the ER membrane (Walter & Johnson 1994).  
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Within the ER lumen newly translated proteins will be able to undergo N-linked 
glycosylation, disulfide bond formation, protein folding and quality control. These secretory 
proteins then leave the ER at ER exit sites in direction of the Golgi apparatus, involving coat 
protein complex II (COPII) coated vesicles (Bannykh et al. 1996; Mogelsvang et al. 2004). 
Transport between the ER and Golgi apparatus is observed to involve pre-Golgi structures 
known as vesicular-tubular clusters (VTCs) or the ER-Golgi intermediate compartment 
(ERGIC). This membrane cluster can be identified by the lectin ERGIC-53, and exhibits 
different properties from both the ER and the cis-Golgi compartments (Saraste & Kuismanen 
1984; Schweizer et al. 1991; Sannerud et al. 2006). 
The detailed mechanisms of how the Golgi apparatus resides as a permanent structure, as well 
as facilitating dynamic transport of cargo, are still unclear. Different models are suggested, as 
described in section 1.1.3 below. The ERGIC will either incorporate with an existing cis-
Golgi cisterna or participate in the construction of a new cis-Golgi cisterna. When entering 
the cis-Golgi apparatus, secretory proteins will then travel through the cis- and medial-Golgi 
apparatus, where O-linked glycosylation occurs, as well as trimming and possible branching 
of N-linked glycans, along the way to the trans-Golgi network (TGN). In the TGN, proteins 
will be sorted and transported to their target destinations, the plasma membrane, for secretion 
or transport to endosomal/lysosomal compartments.  
1.1.2 Golgi apparatus structure, size and localization 
Golgi apparatus structure as observed in the transmission electron microscope (TEM), shows 
several cisternae organized into stacks localized in the perinuclear area. In vertebrate cells, 
the Golgi cisternae and stacks are all one single entity termed the Golgi ribbon (Wei & 
Seemann 2010; Mogelsvang et al. 2004). Many vesicles can be observed around the Golgi 
apparatus, and different models have been suggested to explain their purpose.  
The size and shape of the Golgi complex has high variability, depending on the organism and 
cell type. The Golgi apparatus may consist of individual Golgi cisterna, as found in certain 
yeast cell types, or the stacks themselves can be made of from 2-3 cisterna up to 30 in certain 
euglenoids (Prydz et al. 2008). The Golgi apparatus is usually located in the perinuclear 
region. There are exceptions; however, nerve cells have been observed to have Golgi outposts 
at dendritic branch points, while some Drosophila cell types have been observed to have 
individual stacks distributed throughout the cytoplasm (Prydz et al. 2008).  
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1.1.3 Golgi apparatus models and transport 
There are several models for how secretory proteins move through the Golgi cisternae and 
how resident Golgi proteins are retained in their compartments (Glick & Luini 2011; Prydz et 
al. 2008). Further sorting implications are considered in epithelial cell types that require strict 
sorting to apical and basolateral cell surfaces, or sorting routes that bypass the Golgi 
apparatus entirely (Prydz et al. 2013). This has implications when performing studies with the 
Golgi apparatus, as Golgi apparatus form and function is relatively complex and to some 
degree unknown. Different models can attribute and explain certain things, for example how 
large proteins like procollagen can move through the Golgi complex, but no model explains 
all observations made to date.  
1.1.3.1 Stable compartments model 
In the stable compartments model, the Golgi apparatus sub-compartments are believed to 
have a unique and stable set of resident Golgi proteins. A secretory protein would enter the 
cis-Golgi in COPII-coated vesicles, and would move from one compartment to the next in 
COPI-coated vesicles. Resident Golgi proteins would then be retained in their selective 
compartments through exclusion from COPI-coated vesicles in anterograde traffic. However, 
variations of this model have suggested a bidirectional COPI traffic where escaped resident 
Golgi proteins are returned through retrograde traffic (Orci et al. 2000).  
 
1.1.3.2 Cisternal maturation model 
The cisternal maturation model suggests that the COPII vesicles and VTCs fuse together to 
form the ERGIC, which will mature into a cis-Golgi cisterna, which then gradually matures 
into a trans-Golgi cisterna. This concludes with a fission of the cisterna into secretory 
vesicles and other types of carriers. COPI vesicles would in this model traffic the resident 
Golgi proteins from older to newer (retrograde) cisternae. A variant of this model explains 
why tubules are formed between stacks, where resident Golgi proteins and smaller secretory 
cargo proteins can be transported anterogradely and retrogradely through the Golgi apparatus 
in membrane tubules. 
 
1.1.3.3 Other noteworthy proposed models for Golgi apparatus function. 
In the rapid partitioning model, the Golgi apparatus operates as one compartment with both 
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processing and export domains. Secretory proteins arriving from the ER will rapidly disperse 
into the complete Golgi apparatus through rapid partitioning of vesicles and tubules.  
The rim progression model proposes that the center of the Golgi cisternae are static (Lavieu et 
al. 2013), while proteins in transit through the Golgi apparatus are located at the cisternal 
rims. Secretory proteins are therefore only moving anterogradely from the rims of the Golgi 
cisternae, either in tubules or COPI vesicles.  
In the cisternal progenitor model, the Golgi apparatus has stable compartments with distinct 
domains defined by Rab GTPases (Glick & Luini 2011; Pfeffer 2010). These domains can 
undergo Rab conversion, resulting in a transient “homeotypic” fusion with cisterna in 
adjacent stacks. Secretory cargoes can move forward through the resulting connection. 
Alternatively, a rab domain could pinch off from a cisterna to create a “megavesicle”, which 
would then fuse with a later cisterna in the same Golgi stack. 
1.1.4 Protein sorting signals in the Golgi apparatus 
1.1.4.1 ER retention 
Proteins that are native to the ER are subjects to ER retention mechanisms. Several 
transmembrane proteins of the ER possess a C-terminal lysine, lysine, any amino acid, and 
any amino acid (KKXX) signal, which allows them to incorporate into retrograde COPI 
trafficking vesicles. Soluble ER proteins contain a C-terminal Lys-Asp-Glu-Leu (KDEL) 
signal that favors the binding of the protein to a transmembrane KDEL receptors in the Golgi 
apparatus or ERGIC, which enables the packaging of the protein into COPI retrograde 
vesicles. Other possible retention mechanisms, are based on the length of the transmembrane 
domain of proteins being slotted into cholesterol rich (compared to ER) COPII vesicles, or 
formation of protein multimers in the ER.  
 
1.1.4.2 Golgi signal sorting and protein transport 
The current, dominating view is that, once a protein has entered the Golgi apparatus, the 
primary sorting station is in the TGN.  However, some studies challenged this view. Most 
proteins that enter the secretory pathway have an N-terminus signal peptide, often cleavable, 
that acts as a signal for ER entry. Other signals for guiding the proteins to their proper 
destinations reside elsewhere in the protein sequence or in post-translationally added 
structures, like glycans. 
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1.1.5 Changes in Golgi morphology after induced DNA damage 
When DNA is damaged, a pathway involving GOLPH3, MYO18A, F-actin and DNA-PK 
causes a rapid dispersal of the Golgi apparatus (Farber-Katz et al., 2014) in mammalian cell 
lines. This dispersal is independent of dispersal that can be observed under apoptosis. 
GOLPH3 is essential for normal Golgi morphology, and functions with F-actin to create a 
tensile force for efficient tubule and vesicle formation (Ng et al. 2013; Dippold et al. 2009). 
This requires the ability for GOLPH3 to link trans-Golgi membrane to F-actin through the 
interaction with MYO18A. GOLPH3’s localization to the trans-Golgi requires binding with 
phosphatidylinositol 4-phosphate. Under chemically induced DNA damage, DNA-PK 
phosphorylates GOLPH3 on residues T143 and T148. This increases the interaction with 
MYO18A, results in increased interact action with F-actin, and causes the Golgi apparatus to 
disperse (Farber-Katz et al., 2014). Dispersal of the Golgi apparatus is still noticeable over 30 
days post treatment with DNA damaging agents. This pathway is shown to be required for 
normal survival following DNA damage, and overexpression of GOLPH3 confers resistance 
to killing by DNA damaging agents.  
1.2 Golgi apparatus dependent glycosylation and 
proteoglycan synthesis 
Proteoglycans (PGs) are a diverse group of macromolecules that are made up of a protein core 
with at least one, but usually many, covalently attached glycosaminoglycan (GAGs). These 
are long, unbranched polysaccharides. The function of a PG is often determined by the GAG 
chains and their further modification pattern, as the GAGs can have a variety of functions, 
from structural support to cell signaling. Since the protein core can have active and enzymatic 
domains, they are able to perform several roles at the same time. GAGs have also shown to 
influence sorting in polarized epithelial cells (Prydz & Dalen 2000).  Commonly, PGs are 
either inserted into the plasma membrane or secreted to the extracellular environment.   
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1.2.1 Proteoglycan synthesis 
The PG protein core is translated in the ER, as most PGs are secreted or membrane bound. 
They then follow the secretory pathway through the Golgi apparatus, where O-linked 
glycosylation occurs and extensive glycan modifications are conducted.  
 
1.2.1.1 Activation and transport of nucleotide-sugars. 
The sugars involved in GAG synthesis are activated nucleotide-sugars in the cytoplasm. 
These nucleotide-sugars are created by removal of pyrophosphate from uridine-5'-
triphosphate (UTP) by a glucosyltransferase. This, in turn, releases energy which is then used 
by the glucosyltransferase to attach a sugar, like glucose-1-phosphate, onto the uridine-5'-
monophosphate (UMP), which results in a UDP-sugar, for example UDP-glucose. Then these 
nucleotide-sugars have to be transported into the Golgi lumen by transmembrane nucleotide-
sugar transporters before they can be used in O-linked glycosylation or branching of N-linked 
glycans.  
1.2.1.2 Attachment of the tetrasaccharide linker 
With the exception of keratan sulphate (KS), which is an N- or O-linked proteoglycan, 
synthesis of other proteoglycans is initiated with a tetrasaccharide linker located on a serine 
(Ser) residue followed by a glycine on the surface of a protein core. This tetrasaccharide 
linker is initiated by the addition of a xylose (Xyl) β(1->O-serine), followed by addition of 
two galactose units, D-galactose (Gal) β(1->4), Gal β(1->3) and a D-glucuronic acid (GlcA) 
β(1->3). The following structure represents the tetrasaccharide linker: ->GlcAβ(1–>3)Galβ(1–
>3)Galβ(1–>4)Xylβ(1->O)Ser. 
1.2.1.3 Attachment of alternating carbohydrate dimers to the linker region 
The GAG chain extends from the linker tetrasaccharide by the addition of two alternating 
monosaccharides. For the heparan sulphate (HS) PGs, the monosaccharides are alternating 
GlcA and N-acetyl-glucosamine (GlcNAc), ->GlcAβ(1->4)GlcNAcα(1->4). Heparin is 
created by the epimerization of the GlcA in HS to iduronic acid (IdoA) and further sulphation, 
->IdoA(2S)α(1->4)GlcNS(6S)α(1->4).  
Chondroitin sulphate (CS) is created by the addition and repetition of alternating GlcA and N-
acetyl-galactosamine (GalNAc) to the tetrasaccharide linker, ->GlcAβ(1->3)GalNAcβ(1->4). 
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Moreover, dermatan sulphate (DS) is created by epimerization of the GlcA in CS to IdoA, -
>IdoAβ(1->3)GalNAcβ(1->4).  
For KS, an oligosaccharide linker region can be both N-linked or O-linked, followed by the 
repeating disaccharide of ->Galβ(1 >4)GlcNAcβ(1->3).  
 
1.2.1.4 Sulphation of glycosaminoglycans 
3-phosphoadenosine 5’-phosphosulphate (PAPS) is synthesized in the cytoplasm by PAPS 
synthase and transported into the Golgi lumen by PAPS transporter 1 (PAPST1) and 2. 
Sulphation of GAGs is then carried out by the sulphotransferases in the Golgi lumen that 
transfer sulphate from PAPS onto a –OH in a sugar moiety, the -N-acetyl moiety in the GAG 
chain, or sulphation of tyrosine on the protein core. A single sugar can have multiple 
sulphation sites. The GalNAc carbohydrate can be unsulphated GalNAc, or sulphated as 
GalNAc(4S), GalNAc(6S), or GalNAc(4S,6S). GlcA can be unsulphated or sulphated as 
GlcA(2S), and IdoA can likewise by unsulphated or sulphated as IdoA(2S). GlcNAc can be 
unsulphated, sulphated as GlcNAc(6S), or the acetyl group is replaced with a sulphate as N-
sulphated glucosamine (GlcNS) or GlcNS(6S). Galactose, which is only present in KS, can be 
unsulphated or sulphated as Gal(6S). 
The utilization of the possible sulphation sites can vary along GAGs, with less sulphated 
regions in between more highly sulphated domains. Coupled with the variations in the protein 
core, the epimerization of GlcA to IdoA and addition of N-linked glycosylation, all of which 
can be a target for sorting signals in the Golgi apparatus, make PGs good candidate cargo 
molecules for studies of Golgi apparatus function.   
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Table 1.2.1: Glycosaminoglycan structure and sulphation  
This table illustrates which hexose and hexosamine that participates in each GAG 
disaccharide. Further, it shows where sulphation can occur, and the link between the 
disaccharides. 
GAG 
Hexuronic acid / 
Hexose Hexosamine Linkage 
Chrondroitin 
sulphate (CS) GlcA / GlcA(2S) 
GalNAc / GalNAc(4S) / GalNAc(6S) / 
GalNAc(4S,6S) ->GlcAβ(1->3)GalNAcβ(1->4) 
Dermatan 
sulphate (DS) 
GlcA / IdoA / 
IdoA(2S) 
GalNAc / GalNAc(4S) / GalNAc(6S) / 
GalNAc(4S,6S) ->IdoAβ(1->3)GalNAcβ(1->4) 
Heparan 
sulphate (HS) 
GlcA / IdoA / 
IdoA(2S) 
GlcNAc / GlcNS / GlcNAc(6S) / 
GlcNS(6S) ->GlcAβ(1->4)GlcNAcα(1->4) 
Heparin GlcA / IdoA(2S) 
GlcNAc / GlcNS / GlcNAc(6S) / 
GlcNS(6S) 
->IdoA(2S)α(1-
>4)GlcNS(6S)α(1->4) 
Keratan 
sulphate (KS) Gal or Gal(6S) GlcNAc / GlcNAc(6S) ->Galβ(1->4)GlcNAcβ(1->3) 
 
1.3 Epithelial cell structure and polarized sorting 
Cells lining the cavities and organs of the body, called epithelial cells, adhere together to form 
tight monolayers with the help of tight junctions. Such monolayers form borders between two 
distinct environments, where molecules cannot freely pass between. Epithelial cells therefore 
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display a polar organization, where the cell membrane is divided into apical and basolateral 
domains facing the different environments.  
1.3.1 Madin-Darby canine kidney cells 
For this thesis, the Madin-Darby canine kidney cell line was used. This is an established 
model cell line for studies of epithelial cells. Growing cells on filters allows in vitro studies of 
an epithelial cell monolayer, with the apical and basolateral environments above and below 
the filter, respectively. The MDCK cells form a tight monolayer on the filter and do not allow 
the passage of molecules from one medium reservoir to the other, unless transport occurs 
actively through the cells. MDCK cells both synthesize and secrete the PGs of the CS and HS 
type (Stoops & Caplan 2014; Svennevig et al. 1995), and exhibit polarized sorting.  
1.3.2 Golgi apparatus morphology in MDCK cells 
During a cultivation period of MDCK cells on an adherent surface, the morphology and 
location of the Golgi apparatus changes (Bacallao et al. 1989). After one day of plating, single 
cells are observed to have adhered to the growth surface, and have microtubules radiating 
from a perinuclear region containing the centrosomes and the Golgi apparatus. After further 
growth, the cells will have reached confluence, and formed tight junctions close to the 
substratum. At this point, the Golgi complex has spread around the nucleus. After five days of 
incubation the cells will have reached their final polarized state, being columnar in shape, 
while the tight junctions will have moved approximately 10 microns upward from the basal 
location. The Golgi complex will have formed a ribbon-like convoluted structure located in 
the apical and perinuclear region.  
1.3.3 Polarized protein sorting in epithelial cells 
Epithelial cell polarity has an effect of protein sorting. As the cell membrane is divided into 
two distinct domains, proteins have to be targeted to the correct membrane domain to uphold 
the polarized organization. In general, sorting signals identified that direct transmembrane 
proteins to the basolateral membrane are embedded in the cytoplasmic tail of the protein core 
structure, while apical signals can be more diverse.  
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Upon leaving the Golgi apparatus, secretory proteins may be sorted directly to the cell surface 
or pass through endosomal compartments (Futter et al. 1995). Additionally, there are 
endosomal compartments that specialize in trafficking to the apical and basolateral 
membrane, respectively (Brown et al. 2000; Sheff et al. 1999). The sorting process can be 
even more complex since subdomains may exist within the plasma membrane, for instance 
where a transmembrane protein could be targeted for insertion into a lipid raft in the apical 
membrane, or into a ciliary region (Garcia-Gonzalo & Reiter 2012). 
 
Precisely where along the secretory pathway most sorting decisions take place is still a topic 
for discussion. Sorting has been proposed to mainly take place in the TGN in MDCK cells 
(Simons K & Wandinger-Ness A. 1990). In more recent studies in yeast and mammalian cells 
there are indications that laterally segregated lipid microdomains might form as early in the 
secretory path as the ER and/or cis-Golgi region (Sarnataro et al. 2004; Muñiz & Riezman 
2000; Morsomme et al. 2003). There is also evidence of Golgi apparatus bypass routes, as 
mentioned in section 1.1.3, that would require sorting to take place already in the ER or 
ERGIC (Prydz et al. 2013).  
1.3.4 Modification of GAGs as an effect on signal sorting in 
epithelial cells. 
Earlier studies have shown that chondroitin sulphate proteoglycans (CSPGs) are preferentially 
transported to the apical surface (Kolset et al. 1999), while HS has been found to be secreted 
mainly basolaterally (Mertens et al. 1996; Svennevig et al. 1995; Kolset et al. 1999). 
Serglycin-GFP is secreted from MDCK cells with mainly CS GAG modification. This PG has 
been utilized as a model PG for studies of trafficking in MDCK II cells. In these studies it has 
been observed that the CS on Serglycin-GFP has a higher degree of sulphation when secreted 
basolaterally compared to the counterpart secreted apically (Tveit et al. 2005).  
Further sulphation studies have been performed by changing the expression levels of the 
transmembrane Golgi resident protein PAPST1. Increasing the expression level of PAPST1 
(with a GFP tag), increases the amount of available PAPS in the lumen of the Golgi 
apparatus, and has been shown to increase the sulphation of CS in the apical pathway (Dick et 
al. 2008). Performing a knock-down experiment where the expression of PAPST1 is reduced 
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leads to an increase in sulphation level of a particular HSPG in the basolateral pathway (Dick 
et al. 2015).  
O-glycosylation with glycans of the mucin type has also been shown to be  important for 
apical sorting by treatment with glycosylation inhibitors (Slimane et al. 2000)  
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2 Materials and Methods 
2.1 Cell culture work 
 
The cells used in this thesis were adherent Madin-Darby canine kidney epithelial (MDCK) 
cells. The MDCK II cell line is one of two subclones of the original cell line derived from dog 
kidney, originating either from the distal tubule or the collecting duct of the nephron, and is 
widely used as a model system for studies of polarized epithelia (Herzlinger et al. 1982; 
Simons K & Wandinger-Ness A. 1990; Bacallao et al. 1989). Various cell strains expressing 
different recombinant proteins have been established within the research group after stable 
transfection and clonal selection and are utilized in this work (listed in table 1).  
MDCK cells were for maintenance purposes grown in 75 cm2 flasks with ventilated caps 
containing 20 ml of complete growth medium; Dulbeccos’s modified Eagle’s Medium 
(DMEM), containing 5 % fetal calf serum (FCS) and (1 %) penicillin/streptomycin (P/S). We 
kept the cells in an incubator at 37°C with 5 % CO2 in the incubator atmosphere.  
We performed cell culture work in a laminar cell culture hood in a designated cell lab. 
Table 2.1.1 List of MDCK cell lines used in the investigation. 
This table describes the cell lines that will be used in this thesis. 
Cell Line Description. 
MDCK II Cells from later passages of MDCK.  
MDCK II Serglycin-
GFP MDCK II cells stably expressing serglycin with a C-terminal GFP tag. 
MDCK II Serglycin-
KDEL-GFP 
MDCK II cells stably expressing serglycin with a GFP tag and a KDEL ER-
retention signal. 
MDCK II PAPST1-
GFP MDCK II cells stably expressing PAPST1-GFP. 
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2.1.1 Expansion of cells: Trypsination of MDCK II cells grown in 75 
cm2 flasks 
When adherent MDCK II cells have grown to confluency in 75 cm2 flasks, we expanded them 
to new flasks, to avoid inhibition of further growth and division in confluent epithelial cell 
layers. Ethylenediaminetetraacetic acid (EDTA) was used to open tight junctions creating 
gaps in the otherwise tight monolayer. This in turn allows apically added Trypsin to diffuse 
through the monolayer and cleave proteins in the basolateral domain. Some of these proteins 
help the cells adhere to the flask, and this detaches them and suspends the cells into the 
medium.  
 
Protocol: 
 Remove medium from the bottle. 
 Wash cells with 10 mL Phosphate-buffered saline (PBS) containing EDTA. 
 Add 5 mL Trypsin-EDTA to each bottle. Remove after 3-5 min, or when cells are 
beginning to round up. 
 Add 2 mL Trypsin-EDTA and leave the cells in incubator for 10-15 min, or until all 
the cells have detached. 
 Add 10 mL of complete growth medium to the flask, and resuspend the cells. 
 Transfer cells to new bottles. If transferring to new 75 cm2 flasks, then transfer 2 mL 
of the cell suspension to each flask containing 20 mL of fresh complete growth 
medium. 
Protocol for growth of cells on 35 mm MatTek glass bottom dishes: 
MDCK II cells were plated on 35 mm dishes with a central glass coverslip for studies using 
confocal microscopy. This procedure involves an extra step to remove Trypsin from the cell 
medium. The cells are detached with Trypsin as in the protocol above. 
 
Protocol: 
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 After resuspension in 10 mL of complete growth medium, transfer the cells to 
centrifugation tubes. 
 Centrifuge at 1500 x g 4-5 min.  
 While centrifuging, add 2 mL of medium to each MatTek 35 mm dish. 
 Remove supernatant from tubes and resuspend the cell pellet in 10 mL of complete 
growth medium.  
 Add 0.5 mL of cell suspension to each 35 mm MatTek dish. 
2.1.2 Cryopreservation and retrieval of cryopreserved cells 
To allow us to store cells at a low temperature for a longer period of time, we used dimethyl 
sulfoxide (DMSO) in the medium, which works as a cryopreservative by keeping ice crystals 
from forming and lysing the cells during freezing.  
Protocol, cryopreservation: 
 Grow cells in 75 cm2 flasks before trypsination (2.1.1). 
 Transfer the cell suspension to a 15 mL or 50 mL sterile centrifugation tube. 
 Centrifuge cells at 1500 x g for 5 min.  
 Remove supernatant. 
 Add 1 ml of complete medium with 10 % DMSO to the pellet, and resuspend pellet. 
 Transfer cell suspension to a cryotube and place in a -80 °C freezer. 
 After minimum 2 h, transfer the ampule to liquid nitrogen. 
Protocol, retrieval of cryopreserved cells: 
 Thaw the ampule of cells in a water bath at 37 °C. 
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 Immediately after thawing, add to 75 cm2 cell culture flask containing 20 mL of 
complete growth medium. 
 Incubate for 24 h to achieve fully adherent and confluent cell layer. 
2.1.3 Growing cells on filters – for studies of polarized transport 
Epithelial cells, like the MDCK II cell line, are polarized and have two distinct membrane 
domains that are separated by tight junctions, the apical and the basolateral membrane 
domains. To allow epithelial cells to polarize in an in vivo-like manner, we grew the cells on 
porous filters. The nutrition uptake from the medium underneath the filter-grown cell layer 
induces formation of a polarized monolayer. When the cells are grown to confluency, apically 
secreted macromolecules are segregated by the tight monolayer of filter-grown cells from the 
basolaterally secreted macromolecules.  Passage of macromolecules between the cells of the 
monolayer is restricted due to the tight junctions.  
Protocol: 
 Grow cells in 75 cm2 flasks before trypsination (Section 1.3). 
 Transfer cell suspension to a 15 mL or 50 mL tube for centrifugation. 
 Centrifuge at 1500 x g for 5min. 
 Remove supernantant and resuspend pellet in 10 mL complete growth medium. 
 Add 90 mL of complete growth medium to an autoclaved glass petri dish with 6 
polycarbonate filters (each with an area of 4.7 cm2) in appropriate filter holders. 
 Add 1.6 mL of cell suspension to each filter. 
 Incubate for 3-4 days to allow formation of a tight cell layer on the filter. 
 
Protocol, treatment with doxorubicin or Camptothecin 
 Add 2 mL of complete growth medium with chosen concentration of Doxo or CPT to 
(basolateral) wells in a fresh 6 well plate. 
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 Add 1 mL of complete growth medium with chosen concentration of Doxo or CPT to 
(apical) filters, while transferring filters to new wells.  
 Incubate for chosen length of time (4 h to 24 h) to allow for studies of Golgi dispersal.  
Protocol, incubating with 35S-sulphate: 
 Add 2 mL of sulphate-reduced medium with 2 % FBS and the chosen concentration of 
Doxo or CPT to (basolateral) wells in a fresh 6 well plate. 
 Add 1 mL of complete growth medium with chosen concentration of Doxo or CPT 
apically to filters, while transferring filters to new wells.  
 Incubate for chosen period of time (4 h to 24 h) to allow for studies of Golgi dispersal.  
2.1.4 35S-sulphate metabolic labeling of filter-grown cells. 
We labeled the filter grown cells with the 35S radioactive isotope to allow us to study 
synthesis, sorting and modification of PGs and glycoproteins. PGs carry GAGs that are 
sulphated to various degrees in the Golgi apparatus. By using medium with reduced non-
radioactive sulphate and added radioactive 35S-sulphate, it is possible to determine the amount 
of sulphated macromolecules synthesized during a labeling period. Information concerning 
sorting and transport of labeled macromolecules will then be gathered by analysis of the 
apical medium, the basolateral medium and the cell lysate.  
Sulphate is mainly taken up from the basolateral (blood) side of epithelial cells. We therefore 
only added the 35S-sulphate to the basolateral medium at a concentration of 0.2 mCi/ml. We 
used sulphate free medium (Gibco: RPMI 16040) supplemented with 2 % FBS. 
 
 
Protocol: 
 Add 2.0 mL of sulphate reduced medium containing 0.2 mCi/ml of 35S-sulphate and 
working concentrations of Doxo or CPT to basolateral wells on a new 6-well plate.  
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 Add 1 mL of sulphate reduced medium with working concentrations of Doxo or CPT 
to the filters while transferring to the new 6-well plate. 
 Incubate (18 h to 24 h).  
 Transfer filters to new 6-well plates on ice. 
 Remove and store apical and basolateral medium for analysis. 
 Wash cell filters with 2.0 mL of PBS apically and 2.5 mL PBS basolaterally for 15 
min on tilt table 2 times. 
 Lyse cells with 1.5 mL 1 % Nonidet P-40 (NP-40) lysis buffer on apical filter on tilt 
table for 30 min.  
2.2 Biochemical analysis of sorted 35S-sulphate 
labeled macromolecules. 
2.2.1 Isolation of metabolically labeled macromolecules 
Non-incorporated 35S-sulphate had to be removed before further analysis, so it would not 
interfere with detection of the labeled macromolecules during scintillation counting and 
phosphorimaging of SDS-PAGE gels. We performed gel filtration with Sephadex G-50 Fine 
of cell media and lysates. While macromolecules were eluted, non-incorporated sulphate was 
left behind in the disposable columns.  
 
Protocol: 
 Prepare columns by adding 10 mg/mL Sephadex G-50 Fine suspended in dH2O until 
columns are 4.0 mL in volume.   
 Load 1.0 mL of dH2O through the gel first, to make sure it has settled. 
 Prepare apical samples which contain less than 1mL of medium by adding 1.0 mL of 
PBS. 
 Load columns carefully with 1.0 mL of sample, so as not to disturb the gel. 
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 Add 1.5 mL of dH2O or PBS for elution, and collect eluate. 
2.2.2 Scintillation counting 
After gel filtration, it is possible to determine the amount of 35S-labeled macromolecules in 
each sample. The scintillation counter will detect nuclear disintegrations in the added 
scintillation fluid through emission of energy from molecules present in the scintillation fluid. 
The prior excitation takes place when scintillation molecules are hit by a β-particle emitted 
from 35S. Since the scintillation counts per minute (cpm) reports detected excitation, it is not 
an exact count of the number of nuclear disintegrations. These results will give a relative 
indication of how many 35S labeled macromolecules there are present in our samples.  
2.2.3 SDS-PAGE: Separation of molecules by molecular mass 
Polyacrylamide gel electrophoresis separates molecules according to their molecular mass in 
a gel when an electric current is applied. SDS is negatively charged and binds to proteins with 
a fairly fixed ratio, making all the proteins in a sample negatively charged and thus able to 
move in the same direction in an electric field.  
For this thesis, premade BioRad SDS-PAGE gradient (4-12 %) gels were used, these gels give 
a good range of separation of larger PGs in the upper half of the gels. 
  
Protocol: 
 Prepare 30 µL of each sample in Eppendorf tubes.  
 Add 2 µL (20 x) XT reducing agent and 10 µL (4 x) XT sample buffer to each sample. 
 Heat samples at 96 °C for 5 min. 
 Spin samples down in a table top centrifuge at 1500 x g for 5 min. 
 Place gels in the electrophoresis chambers. 
 Add (1 x) XT-MOPS Running buffer until you reaching the marked lines on the 
chambers. Tilt gels to remove any bubbles that might accumulate underneath the gels. 
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 Load 40 µL of each sample to each well, if using 12+2 well gels. Alternatively, load 
30 µL if using 18+2. 
 Run gels at 90 A per gel for 90 min (should start out at around 120 V), or until blue 
dye has reached the bottom of the gel. 
 When complete, remove the gels from their chambers, and use a spatula to release the 
gel from the plastic cassette and mark the orientation of the gels.  
 Slide the gel off the plastic cover, and into fixation solution.  
 
2.2.4 Fixation and drying of gels. 
Fixation keeps the protein fixed in the gel at their location by preventing the diffusion of the 
proteins through the gel. Once the gel is in the fixation solution, it can be kept there for 
minimum an hour, but also up to several days. It is also possible to bathe the gels in a signal 
amplification solution. However, we find that this is not necessary for 35S-detection. 
 
Protocol: 
 Fix solution is made of 1 part methanol, 1 part acetic acid, and 5 parts of water. 
 Place the gels in a container with fixation solution. 
 Leave for minimum 30 min on a tilt table. 
 Transfer the gels to new containers with dH2O, and leave on a tilt table for 15 min to 
wash away the fixation solution. 
 (Optional) Incubated 15-30 min in Amplify on tilt table for increased detection 
sensitivity. 
After fixation, the gel needs to be dried before it can be further analyzed by phosphorimaging. 
This is done by placing the gels on a piece of filter paper in a vacuum sealed gel dryer for 4 h 
at 70 °C, or until there is no remaining liquid in the tubing to the vacuum pump. After which, 
the gel will be adhered to the paper. 
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2.2.5 Detection: Phosphorimaging 
To visualize radioactively labeled macromolecules in SDS-PAGE gels, we use a Typhoon 
Phosphorimager. This is done by first clamping the gel filter paper to phosphor screens that 
absorb the beta particles from the dried gel for 24 h. We then scan the screens to get a 
measure of the size distribution and quantity of 35S labeled macromolecules. The resulting 
images were then analyzed using the computer program ImageQuant. Figure 2.2.5.1 
illustrates how lanes are marked (Figure 2.2.5.1.A) and how the program quantifies the signal 
peaks and areas under curves after lane marking and background subtraction (Figure 
2.2.5.1.B). The results can then be exported as a numerical measurements to excel. 
 
A) Marking of lanes. 
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B) Signal detection in lanes. 
Figure 2.2.5.1: Example of ImageQuant and signal detection. 
This illustrates lane marking and measurement of signals from the lanes. The red curves 
represent the lanes 1, 2 and 3 from A, and the green curves represent lanes 4, 5 and 6. The 
numbers in the blue boxes are labeled peaks from one of the lanes. The purple line represents 
the background noise from the gel picture, and is deducted from the calculated area under the 
curves.  
 
2.3 Cellular imaging 
2.3.1 Live imaging – end point 
Every sample used for visualization in the confocal microscope for this thesis, had their 
images taken in a z-stack series. This allowed for selecting the plane with the highest Golgi 
complex dispersal. In most cases, the highest x and y dispersal can be found around the cell 
center, or slightly apical to this region. Whenever a comparison was done between one 
selected sample picture and another, the areas with the highest dispersal were chosen. When 
two or more pictures were used to compare a sample, one picture was usually chosen from the 
bottom of the cell. This is done to showcase any possible z-plane dispersal. Bias is avoided by 
the fact that images from control cells are also chosen based on maximum Golgi dispersal. 
The only exception to the z-stack rule, is when doing time lapse microscopy. The images in 
the time-lapse series are scanned in one plane only. The objective used in this thesis was 60X 
in oil with 1.35 numerical aperture. GFP was scanned using 488 nm excitation and 510 nm 
emission detection.  
Image analysis was done for the most part in ImageJ with the Bio-Formats package.  
3D rendering and analysis was done with iMaris. 
 
2.3.1.1 Kalman filter and sequential imaging 
The microscope settings we used for every image were the kalman filter and sequential image 
taking. Kalman setting was set to 4 in all pictures with the exception of time-lapse. When we 
took 4 pictures for each color channel, and take an average of the signaling between those 4. 
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This helps to reduce background noise and sharpens the signals. Taking the pictures 
sequentially between the lasers wavelengths helps to reduce bleed-through of signals from 
one channel to the other. All cells in this section were grown in 35 mm MatTek glass bottom 
culture dishes, all imaging was done live, and all pictures were taken using the inverted 
Olympus FLUOVIEW FV1000 confocal laser scanning microscope. 
2.3.2 Fluorescent marker: Hoechst 33258 
The Hoechst dye binds to the minor groove of double stranded DNA, and it is membrane 
permeable and will bind to DNA and stain the nucleus in live cells. The interaction with DNA 
gives a fluorescent complex with maximum absorbance at 352 nm and maximum excitation at 
461 nm, compatible with both the RFP and GFP spectra. 
Protocol: 
 Grow MDCK II cells to confluency in 35 mm MatTek glass bottom dishes or on 
polarized filters.  
 Add 1 µM of Hoechst 20 min prior to visualization. 
 Wash with 1.0 mL PBS, two times.  
 Add 1.0 mL Phenol-red free medium to dish. 
 Image in fluorescence confocal microscope using 405/422 nm. 
2.3.3 BODIPY® TR Ceramide complexed to BSA 
The ceramide glycolipid precursor forms a complex with BSA, making it possible to add this 
lipophilic fluorescent marker directly to a protein-free cell medium. After uptake, the 
fluorescent sphingolipids will be incorporated into cellular membranes, but will most 
prominently be present in Golgi membranes, as reported by ThermoFisher. This marker has 
maximum absorbance at 589 nm and maximum excitation at 617 nm. 
Protocol: 
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 Grow MDCK II cells to confluency in 35 mm MatTek glass bottom dishes or on 
polarized filters.  
 Incubate in 5.0 µM of BODIPY-TR-Ceramide-BSA in serum-free medium for 30 min 
prior to visualization. 
 Wash with 1.0 mL PBS, two times.  
 Add 1.0 mL Phenol-red free medium to the dish. 
 Image in fluorescence confocal microscope using 559/583 nm. 
2.3.4 CellLights Golgi-RFP, BacMam 2.0 
This marker is a transient transfection which leads to the expression of the Golgi apparatus 
localized protein N-acetylgalactosaminyltransferase (GalNAc-T) with an RFP tag. This 
localization is potentially more towards the trans-Golgi region than towards the cis-Golgi 
side. It has maximum excitation at 555 nm and maximum emission at 584 nm. 
 
Protocol: 
 Grow MDCK II cells  to 70 – 80 % confluency in 35 mm MatTek glass bottom dishes 
or on polarized filters.  
 Add Golgi-RFP to a concentration of 30 parts per cell (PPC) Golgi-RFP 24 h prior to 
visualization (calculate by assuming a maximum cell density of 106 cells in 35 mm 
dish).  
 If needed, add 1x BacMam enhancer and incubate for 1 h. 
 Wash with 1.0 mL PBS. 
 Add 1.0 mL Phenol-red free medium to dish. 
 Image in confocal microscope using 559/583 nm. 
2.4 Cell viability assays 
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For this thesis, we used chemically induced DNA damaging agents in concentrations that 
could kill the cells or cause apoptosis (Tacar, Sriamornsak & Crispin R Dass 2013; Dippold et 
al. 2009; Liu et al. 2000). The biochemical experiments were conducted on whole populations 
of cells in a dish or on a filter, therefore a cell viability assay was needed to establish 
reproducible and reliable experimental conditions. 
2.4.1 Viability assay: Trypan blue stain 
One cell viability assay is the Trypan blue exclusion test, which works on the premise that 
dead cells have leaky and permeable membranes. This allows water-soluble molecules to pass 
into the cell interior and stain the cells in a blue color. Live and viable cells will have a solid 
non-blue core. These can then be manually counted under a microscope or one can employ an 
automatic cell counter. We employed the CountessTM automated cell counter for this task. 
 
Protocol: 
 Add CPT or DOXO depending on amount being tested, for the required period of 
time. 
 Remove the medium after the incubation. 
 Wash cells with 1 mL of PBS with EDTA. 
 Add 0.5 mL of Trypsin-EDTA. 
 Incubate for 15 min, or until all cells have detached from the substratum. 
 Add 2 mL of cell growth medium, then transfer to centrifugal tubes. 
 Centrifuge at 1500 rpm for 5 min. 
 Remove supernatant and resuspend pellet in 1mL of cell growth medium 
 Add 10 µL of the cell suspension to a new tube. 
 Add 10 µL of Trypan blue (0.4 %) and mix well by pipetting. 
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 Remove 20 µL of Trypan blue stained cell suspension and add to CountessTM cell 
counter slide.  
 Insert slide into CountessTM, focus the counter properly (live cells have a bright center, 
dead cells have a dark center) and count the cells. 
 
2.4.2 Viability assay: Propidium iodide assay 
Propidium iodide (PI) is a membrane impermeable compound with fluorescent properties 
when interacting with nucleic acids, interlacing with DNA between guanine and cytosine. It 
has an excitation maximum of 535 nm and emission maximum at 617 nm, when bound to 
DNA in aqueous solution. It also binds to RNA in the same manner. 
 
Protocol: 
 Grow MDCK II cells to confluency in 35 mm MatTek glass bottom dishes. 
 Add Doxo or CPT at working concentrations and incubate for 24 h. 
 Add 300 mL of 0.5 mM PI, incubate for 60 min. 
 Wash with 1 mL of PBS. 
 Add 1 mL of Phenol-red free medium. 
 Image in confocal microscope using 488/604. 
 
2.5 DNA damaging agents, growth media and 
solutions 
2.5.1 DNA damaging agents 
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Doxorubicin: 
Doxorubicin (Doxo) is a drug used in cancer chemotherapy, which intercalates into DNA and 
inhibits the progression of topoisomerase II, as it stabilizes the topoisomerase II complex after 
having introduced a break in the DNA strands. Doxo can also induce apoptosis through the 
Bcl-2/Bax pathway (Tacar, Sriamornsak & Crispin R. Dass 2013). It has also been reported 
that Doxo may lead to an increase in free radical production (Rossi 2013).  
Camptothecin: 
Camptothecin (CPT) has analogues used in cancer chemotherapy. The mechanism of action is 
to bind and stabilize the topoisomerase I DNA complex, which prevents DNA from re-
ligating (Liu et al. 2000).   
2.5.2 Growth media 
Complete MDCK II cell growth medium:  
Lonza DMEM 4.5 g/L glucose w/ L-glutamine. DMEM is a growth medium that contains 
four times the concentration of amino acids, vitamins and supplementary components 
compared to the Basal Medium Eagle (BME). We also modified this with 5 % fetal calf 
serum (FCS) and 1 % penicillin / streptomycin (P/S) to prevent infections and optimize 
growth conditions.  
 
Reduced sulphate medium:  
Gibco RPMI 1640. This medium has all sulphate removed and extra magnesium chloride 
(MgCl2). We also add 2 % FCS to make it more compliant with our MDCK II cells. 
 
Phenol red free medium:  
Gibco Opti-MEM (1X). This medium has increased L-Glutamine, HEPES and no phenol red, 
to reduce background when imaging. 
 
2.5.3 Solutions 
Fix solution:  
1 part methanol, 1 part acetic acid, and 5 parts of water. 
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Lysis buffer with NP-40: 
1 % (5 mL) Nonidet P-40, 2 mM (0.3722 g) EDTA, 35 μg/ml (17.5 mg) PMSF, 150 mM 
(18.75 mL of 4 M) NaCl and 50 mM (25 mL of 1 M) Tris-HCl (pH 7.5). Adjust volume to 
500 mL using MQ water.  
 
10 x PBS:  
2.62 g NaH2PO4  x H2O, 14.42 g NaH2PO4  x 2H2O, 87.66 g NaCl. Mix NaH2PO4  x H2O and 
NaH2PO4 x 2H2O with 300 mL dH2O while stirring. Add NaCl stepwise. At the end, add 
dH2O to 1 L. Adjust pH to 7.4 before autoclaving. 
10 x PBS with EDTA: 
2.62g NaH2PO4  x H2O, 14.42 g NaH2PO4  x 2H2O, 87.66 g NaCl and 18.64 g EDTA. Mix 
NaH2PO4  x H2O and NaH2PO4  x 2H2O with 300 mL dH2O while stirring. Add NaCl 
stepwise, then EDTA. At the end, add dH2O to 1 L. Adjust pH to 7.4 before autoclaving. 
Cryomedium:  
Add sterile filtered 10 % DMSO to complete cell growth medium with 10 % FBS.  
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3 Results 
3.1 Visualizing the Golgi apparatus: Cell lines and 
Golgi markers. 
Since DNA damaging agents have been reported to cause changes in Golgi morphology and 
in the localization of certain Golgi-associated proteins in HeLa cells (Farber-Katz et al. 2014), 
we wanted to address whether proteoglycan (PG) synthesis is affected by such treatment, 
since PG synthesis is a major function of the Golgi apparatus in mammalian cells, and 
changes in PG synthesis are also observed during cancer development. We aim at studying 
this in non-transformed MDCK cells. In these cells, we have good knowledge of PG synthesis 
(Prydz & Dalen 2000; Grøndahl et al. 2009), and the cell line is derived from an epithelium, 
which is the starting point of most cancer types. 
3.1.1 CellLight Golgi-RFP, BacMam 2.0 marker experiments 
A straightforward way to visualize the Golgi apparatus is by transfecting MDCK II cells with 
CellLight® Golgi-RFP (Figure 3.1.1.1) according to the manufacturer’s instruction (Section 
2.3.4: CellLights Golgi-RFP). To easily visualize the cells in a cell monolayer and to have a 
reference for the Golgi apparatus staining in each cell, we also added Hoechst stain to the 
incubations. Therefore, the nucleus of each cell is visualized, making it possible to observe 
the nuclear size and shape.  
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Figure 3.1.1.1: MDCK II cells transfected with CellLight Golgi-RFP, BacMam 2.0.             
MDCK II cells were grown to from 70 % to 80 % confluency and incubated for 24 h with 30 
PPC CellLight Golgi-RFP, followed by incubation with 10 mg/µL Hoechst for 20 min prior to 
visualization. Scale bar; 25 µm. 
As can be observed in the above figure, a low percentage of the cells have been transfected 
with the CellLight Golgi-RFP, BacMam 2.0 reagent. Changing concentrations and incubation 
times did not seem to give significant improvement. It is well known that MDCK cells are not 
easily transfected in the transient mode. ThermoFisher reports that certain cell types might 
benefit from a BacMam enhancer kit to increase the expression of BacMam reagents in 
mammalian cells.   
It is not clearly explained on the manufacturer’s website what the effect of the enhancer 
would be, but it seems to require that the transfection already has taken place. It does not 
seem to increase the transfection efficiency, as the enhancer only helps increase the 
expression level. According to the manufacturer, the transfection vector is the baculovirus. 
Transgenes under the promoter are expressed, but the baculovirus genes and their promoters 
are not recognized in mammalian cells. We decided to perform an experiment with CellLight 
Golgi-RFP, BacMam 2.0 treated with the BacMam enhancer (Figure 3.1.1.2). 
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Figure 3.1.1.2: MDCK II cells transfected with CellLight Golgi-RFP, BacMam 2.0 with 
1X BacMam enhancer. 
MDCK II cells were grown to from 70 % to 80 % confluency and incubated with 30 PPC 
CellLight Golgi-RFP for 24 h, and then treated with 1 x BacMam enhancer solution for 1 h. 
This was followed by incubation with 10 mg/µL Hoechst 20 min prior to visualization. Scale 
bar; 25 µm. 
As can be seen in Figure 3.1.1.2, after transfection, the RFP signal was now distributed in 
vesicle-like structures throughout the cytoplasm of the cells. This is not a typical Golgi 
apparatus localization, evem if the Golgi morphology in MDCK cells is changing 
significantly during polarization of the epithelium (Bacallao et al. 1989).  We therefore 
decided to do a second experiment with the BacMam enhancer present (Figure 3.1.1.3). 
An issue with respect to the concentrations of Golgi-RFP required, was that a 35 mm dish 
may contain up to 106 cells, and calculating the amount of Golgi-RFP revealed that it would 
require around 360 µL of reagent for effective use, which is a high cost for one individual 
experimental point. To work around this issue, we decided to test lower concentrations than 
recommended. 
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A) 5 µL Golgi-RFP                                    B) 10 µL Golgi-RFP   
  
C) 20 µL Golgi-RFP                                  D) 40 µL Golgi-RFP 
Figure: 3.1.1.3: MDCK II cells transfected with CellLight Golgi-RFP, BacMam 2.0. 
MDCK II cells were grown to from 70 % to 80 % confluency, and then incubated for 24 h by 
the listed volumes of CellLight Golgi-RFP, BacMam 2.0, then incubated with 1x BacMam 
enhancer for 1 h, and finally incubated with 10 mg/µL Hoechst for 20 min prior to 
visualization. Scale bar; 50 µm. 
The highest transfection efficiency was obtained at the lower concentration tested (Figure 
3.1.1.3). However, the Golgi-RFP reagent did not transfect the majority of the MDCK II cells, 
making this a sub-optimal choice of Golgi apparatus marker for this cell line.  
3.1.2 BODIPY® TR Ceramide complexed to BSA marker 
experiments 
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Another marker test was carried out with BODIPY® TR Ceramide complexed to BSA 
(BODIPY-TR-Ceramide-BSA) (Figure 3.1.2.1). As was the case for Golgi-RFP, the available 
stock solution from the manufacturer did not allow for a large number of experiments. A 
stock solution of 150 µL with a stock concentration of 0.5 mM, with a working concentration 
of 5.0 µM allowed for fifteen experiments with 1.0 mL of medium. We therefore decided to 
test incubation with lower concentrations of the reagent or with less growth medium. 
   
A) 0.5 µM in 0.5 mL medium B) 0.25 µM in 1,0mL medium  C) 0.5 µM in 1.0 mL medium. 
Figure 3.1.2.1: MDCK II cells treated with Bodipy-TR-Ceramide-BSA. 
MDCK II cells were grown to confluency, then treated for 30 min with the indicated 
concentrations of Bodipy-TR-Ceramide-BSA stock solution, then incubated with 10 mg/µL 
Hoechst for 20 min prior to visualization. Scale bar; 50 µm. 
 
After treatment with BODIPY-TR-Ceramide-BSA treatment we observed that the 5 µM 
marker (5 µl BODIPY-TR-Ceramide-BSA) in 500 µl medium was sufficient to give a visible 
signal similar to what was expected for Golgi membranes (Figure 3.1.2.1). Working with 
medium volumes down to 500 µL is possible for a thirty minute incubation, but it is not ideal 
as it is difficult to ensure that the whole cell layer in a 35 mm dish is covered. The protocol 
for future BODIPY-TR-Ceramide-BSA marker experiments would therefore use 1 mL of 
medium at 5.0 µM.  
Worth noting is that there is a significant background signal when using this type of marker. 
For future experiments with Golgi apparatus dispersal, we would expect a noticeable 
reduction in the signal peaks, and that the concentrated signal in the Golgi apparatus area 
disappears into the background signal. Because experiments with a high background signal 
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are not optimal, we would have to try and find a more specific marker for Golgi apparatus 
visualization, while this marker could be used in the interim and as a complementary method. 
To perform experiments with inducers of DNA-damage over time with observation of Golgi 
apparatus morphology, we addressed the longevity of the BODIPY-TR-Ceramide-BSA 
signal. We had a possible interest in incubating cells for up to 72 h. Therefore, a 35 mm dish 
with MDCK II cells was incubated with 10.0 µM ceramide reagent for 72 h before observing 
in the microscope (Figure 3.1.2.2). 
 
Figure 3.1.2.2: MDCK II cells treated with Bodipy-TR-Ceramide-BSA, incubated for 
72h. 
MDCK II cells were grown to full confluency, treated for 30 min with 5.0 µM Bodipy-TR-
Ceramide-BSA marker, and then incubated with 10 mg/µL Hoechst for 20 min. This was 
followed by a 72 h incubation period prior to imaging. Scale bar; 50 µm. 
Results indicate that the BODIPY-TR-Ceramide-BSA marker needs to be refreshed if long 
incubation periods are of interest (Figure 3.1.2.2). 
3.1.3 MDCK II cells expressing Serglycin-GFP and SG-KDEL-GFP  
An alternative approach was to take advantage of MDCK II cells stably expressing 
fluorescent proteins with predominant or partial Golgi apparatus localization. An available 
cell line (Tveit et al. 2005) was MDCK II cells expressing Serglycin-GFP (Figure 3.1.3.1).  
Serglycin-GFP (SG-GFP) is a protein core with GAG modification sites and follows the 
secretory pathway to the cell surface, where the recombinant PG is secreted. We can therefore 
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expect some signal in the ER, which becomes more concentrated in the Golgi apparatus, and 
also in vesicles trafficking between the Golgi apparatus and the cell membrane. 
As shown in Figure 3.1.3.1.A, employing a cargo molecule that marks the complete secretory 
pathway is concentrated in the Golgi apparatus, but does also significantly label other 
organelles that would give a background labeling in Golgi apparatus dispersal studies. 
Incubation of the cells with 2.0 µM of the DNA damaging agent doxorubicin (Doxo) (Figure 
1.3.1.B) for 24 h indicates some dispersal, but this is difficult to visualize consistently or to 
quantify. 
  
A) Ctrl              B) Doxo, 2.0 µM 
Figure 3.1.3.1: MDCK II cells expressing SG-GFP incubated with 2 µM Doxo. 
MDCK II Serglycin-GFP cells were grown to confluency, then incubated with 2 µM Doxo for 
24 h, and finally with 10 mg/µL Hoechst for 20 min prior to visualization. Scale bar; 50 µm. 
We next investigated the possibility of using MDCK II cells expressing SG-GFP with a C-
terminal KDEL ER retention signal (SG-KDEL-GFP). This KDEL sequence motif (Lys-Asp-
Glu-Leu), mediates retrograde transport from the Golgi apparatus and the ER-Golgi 
intermediate compartment back to the ER (Stornaiuolo et al. 2003). We should therefore be 
able to visualize the Golgi apparatus, the ER, the ER-Golgi intermediate compartment and 
vesicles. 
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A) Ctrl                                                         B) Doxo, 2.0 µM 
Figure 3.1.3.2: MDCK II cells expressing SG-KDEL-GFP, incubated with 2 µM Doxo. 
MDCK II Serglycin-KDEL-GFP cells were grown to confluency, then incubated with Doxo 
for 24 h, and finally with 10 mg/µL Hoechst for 20 min prior to visualization. Scale bar; 50 
µm. 
After 24 h of incubation, the cells were visualized in the confocal microscope. Obviously, 
SG-KDEL-GFP gives a relatively dispersed signal also in untreated MDCK II cells, with no 
clear profile of the Golgi apparatus. A comparison with Doxo treated cells shows putatively 
some more dispersal in treated cells, but this is difficult to quantify (Figure 3.1.3.2, comparing 
A to B). 
3.1.4 MDCK II cells expressing PAPST1-GFP  
The 3'-phosphoadenosine 5'-phosphosulphate transporter 1 (PAPST1) transports 3’-
phosphoadenosine 5’-phosphosulphate (PAPS) from its site of synthesis in the cytoplasm into 
the lumen of the Golgi apparatus where PAPS is the donor of sulphate to sulfotransferases. 
PAPST1 is therefore localized to Golgi membranes. We thus regarded the MDCK II cell line 
expressing PAPST1 with a GFP tag (Dick et al. 2008) as a promising cell line for studies of 
changes in the Golgi apparatus morphology. PAPST1 localizes mostly to the trans-Golgi 
region, and may therefore not give a representative view of the entire Golgi apparatus. It is a 
membrane-spanning protein, so it will remain in Golgi membranes during morphological 
changes.  
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Figure 3.1.4.1 shows that visualization of PAPST1-GFP in MDCK II cells reveals a typical 
Golgi apparatus pattern. Further experiments with addition of Doxo and Camptothecin (CPT) 
indicated significant Golgi dispersal upon treatment with these DNA damaging drugs. The 
MDCK II cell line expressing PAPST1-GFP was therefore a good candidate cell line for 
studies of changes in Golgi apparatus morphology. 
    
A) Ctrl:                                  B) Doxo, 2.0 µM                   C) CPT 4.0 µM 
Figure 3.1.4.1: MDCK II cells expressing PAPST1-GFP incubated with Doxo. 
MDCK II PAPST1-GFP cells were grown to confluency. Doxo and CPT treated cells 
underwent 4 h incubation at the indicated concentrations, followed by 20 h incubation without 
drug, and finally with 10 mg/µL Hoechst for 20 min prior to visualization. Scale bar; 50 µm. 
The only disadvantage of this cell line seems to be a relatively slow growth rate, requiring 
several days extra compared to non-transfected MDCK II cells to reach a confluent cell layer. 
However, there is an advantage in not needing incubation time with a Golgi marker prior to 
drug treatment. Certain marker experiments in this thesis have required up to a 48 h 
incubation time, mainly due to transient transfection to express a Golgi marker.  The transient 
transfection reagents, often lipid-based, may also influence the morphology of cytoplasmic 
organelles. 
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3.2 Incubation with DNA damaging agents and 
changes in the Golgi apparatus morphology 
The aim for this thesis was to investigate possible changes in the Golgi apparatus morphology 
in MDCK II cells upon incubation with DNA damaging agents. It has recently been shown 
that inducers of DNA damage, like doxorubicin (Doxo) and Camptothecin (CPT) also affect 
Golgi morphology dramatically (Farber-Katz et al. 2014). What is important to know about 
Golgi morphology in polarized epithelial MDCK cells, is that under optimal conditions when 
the cell layer becomes completely confluent, the Golgi apparatus will move to the apical part 
of the cell, residing in a perinuclear position, above the nucleus (Bacallao et al. 1989). In less 
confluent cells, that are flatter than the columnar epithelium, the Golgi apparatus is condensed 
so that it will predominate to one side of the nucleus. What we expect after treatment with 
DNA damage inducing agents (Farber-Katz et al. 2014), is that Golgi markers will be more 
widely distributed in the cytoplasm than in control cells, with less concentrated signal in the 
perinuclear area, and a more dispersed signal around the whole nucleus. In our attempt to 
induce this phenomenon, we used the two DNA topoisomerase inhibitors, doxorubicin and 
Camptothecin (Section 2.5.1: DNA damaging agents). 
3.2.1 Induction of changes in Golgi morphology, visualized with 
Golgi-RFP, BacMam 2.0. 
After completing our first investigation of suitable Golgi markers (Section 3.1 Visualizing the 
Golgi Structure), we decided to investigate the effect of Doxo on Golgi morphology  with 
CellLight Golgi-RFP, BacMam 2.0 as the marker of the distribution of Golgi apparatus 
components (Figure 3.2.1.1) in MDCK II cells. What was immediately apparent was that the 
Golgi morphology in cells treated to express CellLight Golgi-RFP seemed dispersed already 
in untreated cells (Figure 3.2.1.1.A). CellLight Golgi-RFP could be observed in a vesicle-like 
pattern all around the nucleus. Cells grown on 35 mm glass bottom dishes might not have a 
perfect tight monolayer, therefore these cells might not be as polarized as they would be when 
grown in vivo or on filter, and it follows that Golgi morphology might not be exactly as 
expected from a 3 – 4 day growth period. However, some of the cells display a more typical 
Golgi morphology and in particular there is a progression towards more dispersal from the 
lowest (2.0 µM) to the highest (4.0 µM) Doxo concentrations (Figure 3.2.1.B-D). 
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A) Ctrl:                                                       B) Doxo, 2.0 µM 
  
C) Doxo, 3.0 µM                                        D) Doxo, 4.0 µM  
Figure 3.2.1.1: Effect of Doxo treatment on Golgi apparatus morphology in MDCK II 
cells, visualized by Golgi-RFP, BacMam 2.0. 
MDCK II cells were grown to from 70 % to 80 % confluency in culture dishes with a 
coverslip at the center, then incubated with Golgi-RFP, BacMam for 24 h, followed by Doxo 
treatment for 6 h at the indicated concentrations, then 10 µg/mL Hoechst was added 20 min 
prior to visualization in the confocal microscope. Scale bar; 50 µm. 
3.2.2 The effect of Doxo treatment on Golgi apparatus morphology 
in MDCK II cells using BODIPY TR Ceramide as the Golgi marker. 
Due to sub-optimal expression of Golgi-RFP, the effect of Doxo on Golgi apparatus 
morphology in MDCK II cells was also investigated using BODIPY TR Ceramide as the 
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Golgi marker. An issue with the ceramide-based marker is a significant background signal, as 
the ceramide-based marker in addition to incorporating into Golgi membranes labels the 
plasma membrane and intracellular vesicles to some extent. 
As can be observed in Figure 3.2.2.1, the ceramide marker displays a brighter staining in the 
perinuclear Golgi region than in the remaining cytoplasm in untreated cells and partially in 
cells treated with 1.0 µM Doxo, while at higher Doxo concentrations, the labeling seems more 
dispersed. Still, there is quite large cell-to-cell variation in Golgi morphology, also in control 
cells, and some loss of cells from the monolayer after treatment with 3.0 µM Doxo, made 
quantification of changes in Golgi morphology difficult. 
  
A) Ctrl                                                        B) Doxo, 1.0 µM 
  
C) Doxo, 2.0 µM                                        D) Doxo, 3.0 µM 
Figure 3.2.2.1: Effect of Doxo treatment on Golgi apparatus morphology in MDCK II 
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cells using BODIPY TR Ceramide as the Golgi membrane marker. 
MDCK II cells were grown to confluency, treated with Doxo for 6 h, incubated for 30 min 
with BODIPY TR Ceramide, and finally incubated for 20 min with 10 µg/mL Hoechst prior 
to visualization. All images were taken using the same laser strength. Scale bar; 50 µm. 
 
Due to some loss of cells at the higher Doxo concentrations, in the next experiment, the effect 
of lower concentrations of Doxo on the morphology of the Golgi apparatus was tested. 
Farber-Katz et al. demonstrated changes in Golgi morphology at concentrations below 1 µM. 
Since they have reported that DNA damage leads to cell death via apoptosis, following the 
GOLPH3 signaling cascade, and the fact that Doxo has been reported to increase cell death 
via apoptosis following the Bcl-2/Bax pathway (Tacar, Sriamornsak & Crispin R. Dass 2013), 
lower concentrations were tested to potentially identify an experimental window where Golgi 
dispersal is induced without significant loss of cells. Farber-Katz et al. were able to detect 
changes in Golgi morphology after 4 h of Doxo treatment of HeLa cells (Farber-Katz et al. 
2014). We therefore decided to treat MDCK II cells for 6 h in the following experiment. 
   
A) Ctrl                                     B) Doxo, 0.05 µM                  C) Doxo, 0.25 µM 
  
D) Doxo 0.5 µM                      E) Doxo 0.75 µM 
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Ctrl                                    Doxo, 0.5 µM                          Doxo, 0.75 µM  
F) Higher magnification 
 
Figure 3.2.2.2: Treatment of MDCK II cells with Doxo and observation of Golgi 
morphology after 6 h, using BODIPY TR Ceramide as marker. 
MDCK II cells were grown to confluency, treated with Doxo or not for 6 h, then incubated for 
30 min with BODIPY TR Ceramide, and finally for 20 min with 10 µg/mL Hoechst, prior to 
visualization. All images were taken using the same laser strength. A-E scale bar; 50 µm, F 
scale bar; 10 µm. 
While 0 – 0.5 µM Doxo gave a predominant perinuclear localization of the lipid-based Golgi 
marker, the marker dispersal was observable after 6 h in the presence of 0.75 µM Doxo 
(Figure 2.1.3.E), particularly evident at a higher magnification (Figure 2.1.3.F).  A reduction 
in the signal seemed to occur already at 0.5 µM Doxo.  
3.2.3 Doxo treatment of MDCK II cells expressing PAPST1-GFP 
Based on the experiments addressing visualization of the Golgi apparatus by fluorescence 
(Section 3.1: Visualizing the Golgi Structure), MDCK II cells stably expressing PAPST1-
GFP were found to be a suitable cell line for studies of Golgi morphology. The first 
incubations with Doxo were carried out for 30 h. This long incubation time might reduce cell 
survival (Section 3.3: Cell viability), but should indicate whether a given Doxo concentration 
leads to  Golgi dispersal, as observed for HeLa cells by Farber-Katz et al. (Farber-Katz et al. 
2014) where the relative Golgi area was tripled after this incubation time. 
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A) Ctrl: Middle plane                                Basal, lower plane  
 
   
B) Doxo, 2.0 µM: Middle plane                Basal, lower plane 
  
C) Doxo, 5.0 µM: Middle plane                Basal, lower plane 
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Ctrl:                                      Doxo, 5.0 µM: 
D) Higher magnification of Basal, lower plane: 
 
Figure 3.2.3.1: MDCK II cells expressing PAPST1-GFP, 30 h of Doxo treatment. 
MDCK II PAPST1-GFP cells were grown to confluency, treated with Doxo for 30 h at the 
indicated concentrations and further incubated with 10 µg/mL Hoechst for 20 min prior to 
imaging. Laser strength was the same across all samples. A-C scale bar; 50 µm, D scale bar; 
10 µm. 
Some loss of cells was observed at the relatively high concentration of 5.0 µM Doxo, 
observable as a loss of cell layer confluency during visualization, but is not observable in 
these images. Figure 3.2.3.1 confirms our earlier results obtained with ceramide based 
marker, and showed that we can observe a dispersal of Golgi elements after treatment with 
both 2.0 µM and 5.0 µM Doxo. At higher magnification (Figure 3.2.3.1.D), it is evident that 
PAPST1-GFP becomes highly dispersed in the cytoplasm of the cells at the highest (5.0 µM) 
concentration of Doxo. 
To reduce the risk of apoptosis and cell death (Section 3.3: Cell viability), the MDCK II 
PAPST1-GFP cell line was incubated with lower Doxo concentrations for a shorter period of 
time (6 h) in an attempt to identify the mildest Doxo treatment that would induce significant 
Golgi dispersal. 
Figure 3.2.3.2 indicates that the Golgi apparatus may seem quite dispersed also in untreated 
samples, and it can be difficult to establish a low level of dispersal at moderate Doxo 
concentrations. The advantage of using PAPST1-GFP as the Golgi marker is a lower level of 
background fluorescence, when compared to BODIPY-TR-Ceramide-BSA.   
52 
 
   
A) Ctrl                                                       B) Doxo, 0.25 µM
   
C) Doxo, 0.5 µM                                       D) 0.75 µM 
Figure 3.2.3.2: MDCK II PAPST1-GFP cells treated with sub-micromolar 
concentrations of Doxo for 6 h. 
MDCK II PAPST1-GFP cells were grown to confluency, treated with Doxo for 6 h at the 
indicated concentrations and further incubated with 10 µg/mL Hoechst for 20 min prior to 
imaging. Laser strength was the same for all samples. Scale bar; 50 µm. 
To investigate whether Hoechst treatment influenced the Golgi apparatus morphology or 
eventually visualization of the Golgi apparatus, an experiment was performed without 
addition of Hoechst towards the end of the experiment. Since treatment with 0.25 µM Doxo 
had not shown indication of Golgi dispersal, the incubations were performed in the presence 
or absence of 0.5 µm, 0.75 µm, 1.0 µM, and 2.0 µM Doxo.  The two latter concentrations 
were below the concentration (3.0 µM) where some loss of cells had been observed.  
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In this experiment (Figure 3.2.3.3) we observed clear indications of Golgi dispersal which is 
most apparent in the basal area of the cell (Figure 3.2.3.3, comparing right panels).  In a 
highly confluent layer of epithelial MDCK cells, there is not much cytoplasmic space 
available at the mid-nuclear level. Thus, it is sometimes easier to observe Golgi dispersal in 
the basal region of the cell, underneath the nucleus. A significant dispersal was observed 
already at sub-micromolar concentration and did not progress with higher Doxo 
concentrations (1.0 µM and 2.0 µM). 
  
A) Ctrl: Middle plane                      Basal, lower plane 
   
B) Doxo, 0.5 µM: Middle plane                Basal, lower plane 
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C) Doxo, 0.75 µM: Middle plane              Basal, lower plane 
 
  
D) Doxo, 1.0 µM: Middle plane                Basal, lower plane 
   
E) Doxo, 2.0 µM: Middle plane                 Basal, lower plane 
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Figure 3.2.3.3 MDCK II PAPST1-GFP cells treated with Doxo, no Hoechst. 
MDCK II PAPST1-GFP cells were grown to confluency, then treated with Doxo for 6 h at the 
indicated concentrations. Laser strength was the same for all samples. Scale bar; 50 µm. 
Previous experiments have shown some loss of cells at 3 to 5 µM Doxo, but primarily after 30 
h of incubation. For the following analysis of Golgi apparatus function, it would be interesting 
to investigate the effect of higher concentrations (up to 5 µM) of Doxo after 6 h of incubation.  
3.2.4 Time-lapse study of doxorubicin treated MDCK II PAPST1-GFP 
cells. 
An alternative way of addressing the effect of Doxo on the morphology of the Golgi 
apparatus is to study the same cell population before and during drug treatment by time-lapse 
microscopy. Due to the potential problem of photo-bleaching during longer time-lapse 
experiments, 10 min intervals for recording images were chosen. The kalman filter and 
sequential imaging were used, but the kalman setting was 2 pictures, instead of the previously 
used 4 (Section 2.3.1: Live Imaging). 
Because the microscope used did not have an autofocus feature, we lost our original focal 
plane between t = 0 min and t = 10 min. Between t = 10 min and t = 360 min we also had a 
gradual shift in the focal plane. This is why Figure 3.2.4.1.A represents a more basally 
localized plane with less of the Golgi apparatus present, compared to Figure 3.2.4.1.C, where 
we see more of the Golgi marker PAPST1-GFP. This is mostly not due to dispersal, but more 
due to a focus z-plane shift from the basal region of the cells towards the middle/apical. 
However, if we select individual cells to follow from t = 10 min to t = 360 min (Figure 
3.2.4.1.D), we can observe some dispersal of the Golgi apparatus despite the change in focus.  
   
A) t = 10 min                          B) t = 180 min                         C) T = 360 min 
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Video: https://youtu.be/tx2hJ4u9Ua0  
 
   
t = 10 min                    t = 180 min                 t = 360 min 
D) Higher magnification of time-lapse images: 
Figure 3.2.4.1: Time-lapse microscopy of MDCK II PAPST1-GFP cells treated with 0.75 
µM Doxo. 
MDCK II PAPST1-GFP cells were grown to confluency, incubated with 10 µg/mL Hoechst 
for 20 min, and then treated with Doxo for continuous visualization up to 6 h. The laser 
settings were the same for all time points and images were recorded every 10 min. A-C Scale 
bar; 50 µm, D Scale bar; 10 µm. 
Due to the shift in z-plane during the time-lapse run and a modest effect of 0.75 µM Doxo on 
the morphology of the Golgi apparatus, the experiment was repeated with 2.0 µM Doxo. To 
try to counteract a shift in focal plane somewhat, the cells were allowed to accommodate for 
15 min in the microscope hood before starting the recording. Otherwise, the experimental 
conditions were as in the first time-lapse experiment, recording images every 10 min.  
Also in this experiment, a shift in the focal plane occurred already between t = 0 min and t = 
10 min, which can be observed in the video link that is provided in Figure 3.2.4.2.E. 
However, we recorded z-stack images at t = 0 min and at the end of the experiment (t = 360). 
This made it possible to address changes in the same focal plane from t = 0 to t = 360 min. 
(Figure 3.2.4.2.C and Figure 3.2.4.2.D). Due to some photo-bleaching, most likely due to the 
extra z-stack images recorded, the signal is less strong at t = 360 min, but it is still evident that 
an intact Golgi structure becomes more dispersed towards the end of the incubation (Figure 
3.2.4.2.D). 
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A) t = 0 min                                                 B) t = 360 min 
 
  
C) t = 0 min                    D) t = 360 min 
Higher magnification from the same focal plane: 
 
E) 6 h time-lapse: https://youtu.be/r00hJ8ckElA 
 
Figure 3.2.4.2: Time-lapse microscopy of MDCK II PAPST1-GFP cells treated with 2.0 
µM Doxo. 
MDCK II PAPST1-GFP cells were grown to confluency, incubated with 10 µg/mL Hoechst 
for 20 min, and then treated with Doxo for continuous visualization up to 6 h. The laser 
settings were the same for all time points, and images were recorded every 10 min. A video is 
available for viewing the complete time-lapse for panel E. One stack of z-images was taken 
before the time-lapse experiment at t = 0 min and again after the end of the time-lapse 
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experiment at t = 360 min, which were used in A and B, respectively. A-B Scale bar; 50 µm, 
C-D Scale bar; 10 µm. 
3.2.5 Camptothecin treatment of MDCK II PAPST1-GFP cells for 
visualization of the Golgi apparatus. 
Induction of DNA damage in combination with studies of Golgi apparatus morphology in 
HeLa cells was studied by Faber-Katz et al. using both Doxo and CPT (Farber-Katz et al. 
2014). The studies using Doxo in this work were therefore complemented with similar studies 
using CPT. 
We find that CPT disperses the Golgi apparatus at 2.0 µM, which is most apparent in the 
image of the basal section (Figure 3.2.5.2.B). GFP excitation in the 5.0 µM sample was 
sparse. Only a few of the adhering cells were giving signal, and there were large gaps in cell 
layer. 
   
A) Ctrl: Middle plane                                  Lower, basal plane 
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B) CPT, 2.0 µM: Middle plane                   Lower, basal plane
  
C) CPT, 5.0 µM: Middle plane 
 
Figure 3.2.5.2: MDCK II PAPST1-GFP cells treated with CPT for 24 h. 
MDCK II PAPST1-GFP cells were grown to confluency, treated with CPT for 24 h at the 
indicated concentrations and incubated with 10 µg/mL Hoechst for 20 min prior to imaging. 
Laser strength was the same for all samples. Scale bar: 50 µm. 
A third experiment with incubation of MDCK II PAPST1-GFP cells in the presence of CPT 
(2.0 to 6.0 µM) was performed (Figure 3.2.5.3). We could observe dispersal of the Golgi 
apparatus in cells incubated in the presence of 4.0 µM CPT (Figure 3.2.5.3.C). All the CPT 
concentrations applied (2.0 to 6.0 µM) lead to Golgi dispersal towards the basal region of the 
cell. Little or no loss of cells from the monolayers could be observed during these 
incubations. 
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A) Ctrl: Middle plane                                               Lower, basal plane 
  
B) CPT, 2.0 µM: Middle plane                               Lower, basal plane 
 
  
C) CPT, 4.0 µM: Middle plane                               Lower, basal plane 
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D) CPT, 6.0 µM: Middle plane                               Lower, basal plane 
Figure 3.2.5.3: Incubation of MDCK II PAPST1-GFP cells in the presence of CPT, 24 h 
treatment. 
MDCK II PAPST1-GFP cells were grown to confluency, treated with CPT for 24 h at the 
indicated concentrations and incubated further with 10 µg/mL Hoechst for 20 min prior to 
imaging. Laser strength was the same for all samples. Scale bar; 50 µm. 
3.2.6 Establishing conditions for biochemical experiments 
We wanted to perform biochemical experiments to address the effects of inducers of DNA 
damage, not only on the structure of the Golgi apparatus, but also on the function of the 
organelle system (Section 3.4: Effect of DNA damaging agents). The function of choice was 
the ability to perform synthesis and sorting of proteoglycans (PGs), monitored by 
investigating the incorporation of 35S-sulphate into PGs and their subsequent secretion into 
the apical and the basolateral media of filter-grown polarized monolayers (Tveit et al. 2005; 
Dick et al. 2008; Grøndahl et al. 2009). Metabolic labeling of PGs with 35S-sulphate may be 
performed over various time-spans, but to obtain sufficient material secreted for several types 
of analysis, incubation for 24 h is often used.  
The biochemical studies should ideally be performed with experimental conditions similar to 
those giving a clear Golgi dispersal and little or no loss of cells from the monolayer. 
Experiments with CPT and Doxo in what seemed to be the optimal concentration range (4.0 
µM or less CPT, and 0.5 µM to 2.0 µM Doxo). The incubation time was now set to 24 h to 
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comply with metabolic labeling conditions.  For these experiments we used MDCK II 
PAPST1-GFP cells with a lower passage number. 
  
A) Ctrl: Middle plane                                             Lower, basal plane 
  
B) Doxo, 0.5 µM: Middle plane                             Lower, basal plane 
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C) Doxo, 2.0 µM: Middle plane                             Lower, basal plane 
Figure 3.2.6.1: Treatment of MDCK II PAPST1-GFP cells with Doxo, cells with low 
passage number. 
MDCK II PAPST1-GFP cells were grown to confluency, treated with Doxo for 24 h at the 
indicated concentrations and further incubated with 10 µg/mL Hoechst for 20 min prior to 
imaging. Laser strength was the same for all samples. Scale bar: 50 µm. 
Interestingly, the low passage cells showed a higher tendency to alter their Golgi morphology, 
especially when comparing cells treated with 2.0 µM Doxo in Figure 3.2.6.1.C with cells with 
higher passage number treated with the same concentration in Figure 3.2.6.2.C. After 24 h of 
treatment, a significant dispersal was observed (Figure 3.2.6.1.C), with PAPST1-GFP also 
present in the basal region of the cells.  
  
A) Ctrl                                                        B) Doxo, 0.5 µM 
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C) Doxo, 2.0 µM                                        D) 4.0 µM CPT 
Figure 3.2.6.2: Treatment of MDCK II PAPST1-GFP cells with Doxo, cells with high 
passage number. 
MDCK II PAPST1-GFP cells were grown to confluency, treated with Doxo or CPT for 24 h 
at the indicated concentrations and further incubated with 10 µg/mL Hoechst for 20 min prior 
to imaging. Laser strength was the same for all samples. Scale bar; 50 µm. 
3.2.7   3D-Modeling 
The confocal microscope can record images at several xy-planes with sub-micrometer 
proximity. A confluent epithelium reaches a height of 10 µm or more (depending on seeding 
conditions). Several xy-planes comprise a z-stack which may be reconstructed into a 3D-
image. For rendering the images in 3D, we use the software iMaris. This tool allows us also to 
perform further signal analysis. After producing modeling quality z-stacks, we were able to 
construct a 3D image from the recorded optical sections (Figure 3.2.7.1).  
For incubations with 0.5 µM Doxo, we did observe some dispersal (Figure 
3.2.7.1.B/3.2.6.1.B), but due to the background cut-off setting of iMaris for green 
fluorescence, it did not model the lower signals. This has an impact on the data in Table 
3.2.7.1, where the Golgi area relative to the nuclear area is reduced in the presence of 0.5 µM 
Doxo in comparison to the control. Since strong signal areas were less frequent in the cells 
treated with 0.5 µM Doxo, with a wide dispersal of a weak signal, this is of course an 
indication of Golgi apparatus dispersal. 
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The cells in the sample treated with 2.0 µM Doxo (Figure 3.2.7.1.C/3.2.6.1.C) are relatively 
larger in size compared to the control cells. This is due to lesser cells, and could be an effect 
of a lower plating density, or an effect of the Doxo treatment, slowing the growth rate or 
inducing some detachment of cells. However, the background cut-off for these cells allowed a 
larger fraction of the Golgi membranes to be rendered in 3D, which is why a large spike in 
relative Golgi area is observed (Figure 3.2.7.2) compared to what is observed for cells treated 
with 0.5 µM Doxo. It is worth noting, when analyzing the 3D-images, that the green 
fluorescence area is generated by the program, and is not related to relative signal saturation.  
 
A) Ctrl 
https://youtu.be/3K8gA3mt5p4  
 
 
B) Doxo, 0.5 µM 
https://youtu.be/uPBPCKgbUTE  
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C) Doxo, 2.0 µM 
https://youtu.be/LAJA1VGyfmU  
 
Figure 3.2.7.1: 3D Modeling of Figure 3.2.6.1: Treatment of MDCK II PAPST1-GFP 
cells with Doxo, cells with low passage number. 
Images rendered in iMaris. Cells used were low passage MDCK II PAPST1-GFP cells 
presented in Figure 3.2.6.1. 
 
 
Figure 3.2.7.2: 3D modeled Golgi area relative to nucleus size. 
Total nuclear signal area (Hoechst) was divided by the total number of detected nuclei in the 
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picture, giving an average size of each nucleus in the picture. Total Golgi signal area 
(PAPST1-GFP) was divided by the number of detected nuclei to give an average Golgi area 
per nucleus. Average Golgi area per nucleus was then divided by average size of each 
nucleus, to give the Golgi area relative to the nucleus size (Table 3.2.7.1).  
 
The experiments have confirmed dispersal of the Golgi apparatus after 24 h treatment of 
MDCK II PAPST1-GFP cells with 2.0 µM – 6.0 µM CPT or 0.5 µM to 5.0 µM Doxo. The 
risk of losing cells from the monolayer upon treatment with 3.0 µM Doxo or more, indicates 
that a cell viability assay is required prior to the biochemical experiments. 
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3.3 Cell viability after incubation with DNA damage 
inducers 
 
GOLPH3 is an oncogene that has been linked to the mTOR pathway (Scott et al. 2009) which 
has multiple metabolic roles, one of which is connected to delivery of cell survival signals 
(Laplante & Sabatini 2009). Following this, Farber-Katz, et al. showed in their 2014 article 
(Farber-Katz et al. 2014) that treatment of HeLa cells with doxorubicin (Doxo) led to an 
increase in apoptotic cell death. What we have observed is that under conditions of higher 
concentrations of Doxo or Camptothecin (CPT), there is a loss of cell layer confluency in the 
microscope. We were therefore interested in determining how many viable cells we have after 
incubation of MDCK II cells with DNA damaging agents, which we can use to gauge the 
optimal dosage for our proteoglycan analysis. We tested two cell viability assays, Propidium 
iodide stain (PI-stain) and Trypan blue stain. 
3.3.1 Propidium iodide stain 
What we observed in the first trial, was that combining Hoechst with a Golgi signal caused a 
signal overflow of the Hoechst stain, leading to an increase in signal noise for the initial run, 
giving a clear positive signal in the control cells (Figure 3.3.1.A, upper left panel). Despite 
this, when the cells were treated with increasing amount of Doxo, there was a larger amount 
of concentrated signal ‘dots’ dispersed in and around the cytosol (Figure 3.3.1D/3.3.1F). This 
indicated that there was indeed a loss of viability at higher concentrations of the DNA 
damaging agents.  
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A) Ctrl:                                   B) Doxo, 0.1 μM                     C) Doxo, 0.5 μM 
    
D) Doxo, 1.0 μM                     E) Doxo, 3.0 μM                    F) Doxo, 5.0 μM  
Figure 3.3.1.1: MDCK II cells treated with Doxo at increasing concentration, PI stain 
with Hoechst present. 
MDCK II cells were grown to confluency in 35 mm glass bottom dishes. They were then 
incubated with Doxo for 6 h at the listed concentrations, followed by a 60 min treatment with 
PI-stain and then treated 30 min with Hoechst. Scale bar; 50 µm.  
Following this, it seemed apparent that using Hoechst was not needed and also caused 
unnecessary signal bleed through, therefore we did a second run without the Hoechst dye 
present (Figure 3.3.2). 
Through visualization of Golgi dispersal induced by DNA damage, we have observed a good 
dispersal of the Golgi apparatus at 0.75 μM of Doxo. We would therefore apply concentration 
in the subsequent experiments, and wanted to test the cell viability at this concentration. We 
were also interested in addressing cell viability at a slightly higher concentration, like 1.0 μM 
Doxo. This resulted in that we actually had more PI signal at the 0.75 μM (Figure3.3.2.B) 
concentration than at 1.0 μM (Figure 3.3.2.C).  
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A) Ctrl                                   B) Doxo, 0.75 μM                C) Doxo, 1.0 μM 
Figure 3.3.1.2:  MDCK II cells treated with Doxo, PI-stain with no Hoechst. 
MDCK II cells were grown to confluency in 35 mm glass bottom dishes. They were then 
incubated with Doxo for 6 h at the indicated concentrations, followed by a 60 min treatment 
with PI-stain. Scale bar; 50 µm. 
3.3.2 Trypan blue cell viability assay 
Due to the inconsistency with the PI stain, we decided to compare the results with a Trypan 
blue cell viability assay. Certain samples were analyzed more than once, and an average was 
generated of these before being plotted (Figure 3.3.2/3.3.3). 
Incubation of MDCK II cells with concentrations below or equal to 5.0 μM Doxo for 24 h did 
not cause a significant loss in viability (Figure 3.3.2.A). Since we noticed some decrease in 
cell count upon treatment with CPT, we also added a graph showing the total amount of cells 
counted in Doxo treated cells compared to control (Figure 3.3.2.A). If the dead cells (or the 
living cells for that matter) were not firmly attached to the dish when they are being prepared 
for Trypan blue stain, they would be removed during the subsequent washing steps. This 
would also be noticeable in Figure 3.3.2.1 when looking at the total number of cells. In the 
case of Doxo treatment, we did not find any reduction in the total cell number. 
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Figure 3.3.2.1: MDCK II PAPST1-GFP cells treated with Doxo, subjected to Trypan 
blue stain (Table 3.3.2). Viability and total cell number relative to control of MDCK II 
PAPST1-GFP cells after 24 h treatment with the indicated Doxo concentration.  
CPT treatment did not reduce the viability dramatically for incubations at 6 μM or less, 
maintaining at least 90 % viability (Figure 3.3.2.2). However, the total number of cells 
declined for incubations with more than 4.0 μM CPT, indicating that cells detach at higher 
concentrations. Therefore, in further experiments, 4.0 μM CPT should be the highest 
concentration. 
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Figure 3.3.2.2: MDCK IIPAPST1 cells treated with CPT, subjected to Trypan blue stain 
(Table 3.3.4). 
Viability and total cell number relative to control of MDCK II PAPST1-GFP cells after 24 h 
treatment of the indicated concentrations of CPT. 
The viability studies suggest that 4.0 μM CPT will be the highest concentration suitable for 
studies of PG synthesis and sorting, and that concentrations of up to 5.0 μM Doxo also allow 
most of the cells to survive (Figure 3.3.2.2). However, occasionally, some loss of cell layer 
confluency was observed at Doxo concentrations between 3.0 and 5.0 μM. Therefore, 2.0 μM 
Doxo was the highest concentration used in studies of PG synthesis and sorting. 
 
  
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
Control 2.0 μM 4.0 μM 5.0 μM 6.0 μM 10.0 μM
P
er
ce
n
ta
ge
CPT concentration
Viability Avg. Total relative to ctrl
73 
 
3.4 The effect of DNA damaging agents on 
proteoglycan synthesis and sorting. 
3.4.1 The effect of Camptothecin on synthesis and secretion of 35S-
sulphate labeled macromolecules  
Treatment of MDCK cells with inducers of DNA damage led to a significant change in the 
Golgi apparatus morphology (Figure 3.2.7.2). We therefore wanted to investigate whether 
these changes also had consequences for some of the functions of the Golgi apparatus. To this 
end, we metabolically labeled polarized, filter-grown epithelial cells with 35S-sulphate to 
address proteoglycan (PG) sorting and secretion in the apical and basolateral direction. The 
initial experiments were carried out by using Camptothecin (CPT) as the inducer of DNA 
damage. We chose to test two cell lines, regular MDCK II cells and MDCK II Serglycin-GFP 
cells, expressing Serglycin with a C-terminal GFP tag, as Serglycin-GFP could be used in 
studies of synthesis and sorting of one individual PG molecule in addition to studies of the 
bulk of PGs secreted.  
The experiment was conducted as described in the methods chapter (Section 2.2: Biochemical 
analysis of proteoglycans). The cells were preincubated with 2.0 µM CPT for 4 h before 
addition of 35S-sulphate to the medium, followed by a 20 h labeling period in the absence or 
presence of CPT.  
At the end of the labeling period, apical media, basolateral media, and cell lysates were 
harvested. Macromolecules were separated from unincorporated 35S-sulphate by gel filtration 
on Sephadex G-50 fine columns and aliquots were subjected to scintillation counting (Figure 
3.4.1.1).  
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Figure 3.4.1.1: Incorporation 35S-sulphate into macromolecules by MDCK II cells and 
MDCK II Serglycin-GFP cells treated or not with 2.0 µM CPT for 4 h and 24 h.Secretion 
of 35S-sulphate labeled macromolecules in the absence (control) or presence of 2.0 µM CPT. 
MDCK II cells (MDCK II) and MDCK II Serglycin-GFP cells (Serglycin-GFP) were 
incubated (4 h and 24 h) or not (Control) for 4 h, before addition of 0.2 mCi/ml of 35S-
sulphate to the medium and further incubation in the absence (Control and 4 h) and presence 
(24 h) of CPT. Labeled macromolecules secreted to the apical or basolateral media or 
remaining in the cell fractions were isolated by Sephadex G-50 Fine and representative 
aliquots were analyzed by scintillation counting. Bars show average of 2 parallel samples. 
Error bars represent the standard error multiplied by 2. (Table 3.4.1.1) 
In the untreated fractions (Control), the major amount of labeled macromolecules is secreted 
to the basolateral media, a lesser amount is secreted apically, and a minor amount is retained 
in the cell fraction (Figure 3.4.1.1). This distribution is observed for both MDCK II cells and 
MDCK II Serglycin-GFP cells. Due to the low sample size, variations between these two cell 
lines could not be established to be significant. 
 
There is an increase in the average of basolaterally secreted macromolecules upon CPT 
treatment for 4 h, but the variation in the parallels and the low number of experiments means 
that this cannot be said to be significant (Figure 3.4.1.1). Basolaterally, 24 h treated cells 
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secreted less labeled macromolecules compared to the control, possibly a significant reduction 
for the MDCK II Serglycin-GFP samples. The apical medium showed an increase in the 
average amount of secreted macromolecules after 24 h of CPT treatment, when compared to 
the control (Figure 3.4.1.1). However, the results in Figure 3.4.1.1 are uncertain due to the 
low number of experiments and the large variation in the parallels. 
The MDCK II Serglycin-GFP samples were subjected to SDS-PAGE. Metabolic label with 
35S-sulphate were mainly incorporated into PGs. Due to modification with GAG chains, these 
are often large in size, and will not migrate far into the gel.  
 
 
Figure 3.4.1.2: MDCK II Serglycin-GFP cells treated with CPT and metabolically 
labeled with 35S-sulphate. 
MDCK II SG-GFP cells were grown on filters to confluency (96 h). Two samples were left 
untreated (C), and two samples were treated for 4 h with 2.0 µM CPT (4h). The last two 
samples were treated for 4 h with 2.0 µM CPT followed by an additional 20 h with 2.0 µM 
CPT (24h). Metabolic labeling was performed for all samples for 20 h. Labeled 
macromolecules secreted to the apical or basolateral media or remaining in the cell fractions 
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were isolated by Sephadex G-50 Fine. SDS-PAGE was then performed. Bands show secreted 
and cellular macromolecules that have been metabolically labeled with 35S-sulphate. 
 
From the SDS-PAGE (Figure 3.4.1.2), we observed that the apical samples have low signal 
strength, with some variation between the parallels. Also the cell lysate samples have some 
variation between the parallels, including in the control samples. The basolateral samples 
have bands stronger than untreated (control) samples after 4 h of treatment, but bands with 
less signal than untreated cells at 24 h (Figure 3.4.1.3.B). The variation between 4 h and 24 h 
treated basolateral fractions could possibly indicate a concentration and/or time dependent 
change in secretion.  
3.4.2 The effect of doxorubicin on synthesis and secretion of 35S-
sulphate labeled macromolecules by MDCK II PAPST1-GFP cells 
Doxorubicin (Doxo) was employed in a second trial to investigate effects on polarized PG 
synthesis and secretion in epithelial cells. For this experiment, we use another sub-cell line of 
MDCK II cells expressing PAPST1-GFP. Due to the PAPST1-GFP cells expressing increased 
amounts of the PAPST1 protein, these cells exhibit higher levels of sulphation of apically 
sorted chondroitin sulphate (CS) (Dick et al. 2008). We also used this cell line for the 
majority of the Golgi apparatus imaging experiments in Section 3.2, and for cell death assays 
in Section 3.3, allowing us to compare results in this section with those presented in earlier 
sections.  
To study the effects of Doxo on sorting of labeled macromolecules, the cells were treated with 
0.25 µM Doxo, 0.5 µM Doxo, and 0.75 µM Doxo. 0.25 µM Doxo had previously not been 
observed to induce Golgi dispersal in MDCK II PAPST1-GFP cells, but we were interested to 
investigate whether this concentration could still affect PG sorting. We increased our initial 
incubation time with Doxo to 6 h, for which we had previously observed the Golgi apparatus 
to be dispersed (Section 3.2: Incubating with DNA damaging agents). Subsequently, we 
initiated metabolic labeling for 18 h with 35S-sulphate in the continued presence of Doxo. 
This combines to a total 24 h Doxo treatment time.  
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Figure: 3.4.2.1: Synthesis and secretion of 35S-sulphate labeled macromolecules by 
MDCK II PAPST1-GFP cells treated with 0.25 µM, 0.5 µM or 0.75 µM Doxo (Table 
3.4.2.1). 
Secretion of 35S-sulphate labeled macromolecules in the absence (Control) or presence of 0.25 
µM, 0.5 µM, or 0.75 µM Doxo. MDCK II PAPST1-GFP cells were grown on filters to 
confluency (96 h). The cells were incubated for 6 h before addition of 0.2 mCi/ml of 35S-
sulphate to the medium and further incubation in the presence (24 h total) of Doxo. Labeled 
macromolecules secreted to the apical and basolateral media or remaining in the cell fractions 
were isolated by Sephadex G-50 Fine and representative aliquots were analyzed by 
scintillation counting. Bars show average scintillation counts of 3 (2 of 0.75 µM, apical 
medium) parallel samples. Error bars represent the standard error multiplied by 2. (Table 
3.4.2.1). 
Upon Doxo treatment, there was a gradual decline in the apical secretion of 35S-sulphate 
labeled macromolecules (Figure 3.4.3.1/Table 3.4.3.1). For the basolateral medium, we could 
not observe a corresponding decline in the secretion of sulphated macromolecules, but rather 
a possible increase (not necessarily significant) for the samples treated with 0.5 µM Doxo, 
which was also observed for the cell lysates (Figure 3.4.2.1). The samples were further 
analyzed by SDS-PAGE. 
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A) apical and basolateral medium      B) Cell lysates 
Figure 3.4.2.2: SDS-PAGE of samples from MDCK II PAPST1-GFP cells treated with 
0.25 µM, 0.5 µM or 0.75 µM Doxo. 
Secretion of 35S-sulphate labeled macromolecules in the absence (Ctrl) or presence of 0.25 
µM (250), 0.5 µM (500), or 0.75 µM Doxo (750). MDCK II PAPST1-GFP cells were grown 
on filters to confluency (96 h). The cells were then incubated for 6 h before addition of 0.2 
mCi/ml of 35S-sulphate to the medium and further incubation in the presence (24 h total) of 
Doxo. Labeled macromolecules secreted to the apical or basolateral media or remaining in the 
cell fractions were isolated by Sephadex G-50 Fine. SDS-PAGE was then performed. Bands 
show secreted macromolecules that have been metabolically labeled with 35S-sulphate. 
We observed some cracking towards the bottom of the SDS-PAGE gels, due to insufficient 
drying (Figure 3.4.2.2), the PGs, however, are mainly located at the top of the gel. The apical 
gel showed a possible reduction in signal at 0.75 µM, which could also be the case for the 
basolateral samples. The lysate gel has two bands of interest in each sample, an upper band 
and one further into the gel. The upper band increases in signal density with increased Doxo 
concentration, while the lower band seems to remain unchanged (Figure 3.4.2.2). Further 
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quantification of the gels was performed using ImageQuant TL. 
 
 
Figure 3.4.2.3: Quantification of SDS-PAGE gels of 35S-sulphate labeled macromolecules 
synthesized by MDCK II PAPST1-GFP cells treated with 0.25 µM, 0.5 µM or 0.75 µM 
Doxo. Apical and basolateral media (Table 3.4.2.3).  
The chart was created using numerical values from Appendix Table 3.4.2.3. These numbers 
represent the average area and strength of each upper band in the apical and basolateral gels 
from Figure 3.4.2.2, as generated using ImageQuant TL. This graph is representative for 
changes in apically and basolaterally secreted macromolecules after treatment with 0.25 µM, 
0.5 µM or 0.75 µM Doxo. The Y-Axis has arbitrary units, representing quantitation by 
ImageQuant of radioisotopic signals detected by phosphorimager screens scanned in a 
Typhoon 9400 FLA laser scanner. Error bars represent the standard error multiplied by 2 
(Table 3.4.2.3). 
After analysis of the apical and basolateral medium samples (Figure 3.4.2.3), we observed a 
reduction in signal strength of the upper band for the apical samples for cells treated with 0.50 
µM and 0.75 µM, when Doxo compared to untreated (Control). At 0.25 µM Doxo we 
observed an increase in signal strength, which could be an indication of a concentration 
dependent change in apical secretion (Figure 3.4.2.3). For the basolateral samples, there is 
more variation in the signals from the Doxo treated-samples (Figure 3.4.2.3). It is not possible 
to conclude whether there has been a significant change in PG secretion to the basolateral 
medium during Doxo treatment.  
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The Y-Axis has arbitrary units, represents quantitation by ImageQuant of radioisotopic 
signals detected by phosphorimager screens as scanned in a Typhoon 9400 FLA laser scanner. 
 
Figure 3.4.2.4 SDS-PAGE of 35S-labeled macromolecules synthesized by MDCK II 
PAPST1-GFP cells treated with 0.25 µM, 0.5 µM or 0.75 µM Doxo, 2 bands in cell lysate. 
(Table 3.4.2.3). 
The chart presents numerical values from Table 3.4.2.3. These numbers represent the average 
area and strength of each upper and lower bands in the gel with the lysate samples (Figure 
3.4.2.2), as generated using ImageQuant TL. This graph is representative for changes in 
macromolecules retained in the cell lysate after treatment (or not) with 0.25 µM, 0.5 µM or 
0.75 µM Doxo.  Error bars represent the standard error multiplied by 2 (Table 3.4.2.3). 
There was an increase in the upper band signal strength after treatment with 0.5 µM and 0.75 
µM Doxo (Figure 3.4.2.4). The 0.25 µM sample increase is not as noticeable, and the error 
bar has overlap with the untreated (Control) sample. The middle band does not have a clear 
indication of any change in signal strength after treatment with Doxo.  
3.4.3 The effect of doxorubicin and Camptothecin on synthesis and 
secretion of 35S-sulphate labeled macromolecules in MDCK II 
PAPST1-GFP cells 
Due to variations between parallels and relatively large error bars (due to few samples) 
between average concentrations, it was decided to do a third 35S-sulphate labeling experiment. 
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For this experiment we used both CPT and Doxo. We had earlier deduced (Section 3.3: Cell 
viability) that we could incubate MDCK II PAPST1-GFP cells for 24 h in the presence of 4.0 
µM Doxo and still retain > 90 % viability. We have also concluded that MDCK II PAPST1-
GFP cells can be incubated for 24 h with 2.0 µM Doxo and retain > 90 % viability. This 
would be the upper limit concentrations of what we could use. We also decided to incubate in 
the presence of 0.5 µM Doxo, due to earlier Doxo experiments showing high variation 
between parallels at this concentration. 0.5 µM also represents the lowest concentration where 
we have observed a change in Golgi structure (Section 3.2: Incubation with DNA damaging 
agents).  
 
Figure: 3.4.3.1: Scintillation count of samples from MDCK II PAPST1-GFP cells treated 
with 0.5 µM or 2.0 µM of Doxo, or 4.0 µM CPT (Table 3.4.3.1). 
Secretion of 35S-sulphate labeled macromolecules in the absence (Control) or presence of 0.5 
µM Doxo, 2.0 µM Doxo, or 4.0 µM CPT. MDCK II PAPST1-GFP cells were grown on filters 
to full confluency (96 h). The cells were incubated for 6 h before addition of 0.2 mCi/ml of 
35S-sulphate to the medium and further incubation in the presence (24 h total) of Doxo or 
CPT. Labeled macromolecules secreted to the apical or basolateral media, or remaining in the 
cell fractions were isolated by Sephadex G-50 Fine and representative aliquots were analyzed 
by scintillation counting. Bars show average scintillation counts of 3 (2 of 0.5 µM Doxo) 
parallel samples. Error bars represent the standard error multiplied by 2 (Table 3.4.2.1). 
What we could observe from the scintillation counting (Figure 3.4.3.1), was a significant 
reduction of the signal in samples treated with 4.0 µM CPT and 2.0 µM Doxo in the cell 
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lysates, the apical medium and the basolateral medium in comparison to the untreated 
(Control) samples. Further analysis was done by SDS-PAGE.  
 
A) Apical media and cell lysates              B) basolateral media 
Figure 3.4.3.2: SDS-PAGE of samples from MDCK II PAPST1-GFP cells treated with 
0.5 µM or 2.0 µM Doxo, or 4.0 µM CPT.  
Secretion of 35S-sulphate labeled macromolecules in the absence (Ctrl) or presence of 0.5 µM 
Doxo (0.5D), 2.0 µM Doxo (2D), or 4.0 µM CPT (CPT). MDCK II PAPST1-GFP cells were 
grown on filters to confluency (96 h). The cells were then incubated for 6 h before addition of 
0.2 mCi/ml of 35S-sulphate to the medium and further incubation in the absence, or presence, 
(24 h total) of Doxo. Labeled macromolecules secreted to the apical or basolateral media or 
remaining in the cell fractions were isolated by Sephadex G-50 Fine. SDS-PAGE was then 
performed. Bands show macromolecules that have been metabolically labeled with 35S-
sulphate. 
As was observed for the scintillation counts, there was a significant reduction in 35S-labeled 
macromolecules in the cell lysate (Figure 3.4.3.2.B). There was a lesser separation of the 
upper and lower bands in the cell lysate samples.  
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A) Apical medium and lysate. 
 
 
B) Basolateral medium 
Figure 3.4.3.3: SDS-PAGE of samples from MDCK II PAPST1-GFP cells treated with 
0.5 µM and 2.0 µM of Doxo, and 4.0 µM CPT (Table 3.4.3.2). 
A) The chart presents numerical values from Appendix Table 3.4.3.2. These numbers 
represent the average area and strength of each top and middle band in the apical medium and 
cell lysate samples from Figure 3.4.3.2.A, as generated using ImageQuant TL. This graph 
describes the labeled macromolecules in the SDS-PAGE gels with samples of apical medium 
and cell lysates after treatment (or not) with 0.5 µM Doxo, 2.0 µM Doxo, or 4.0 µM CPT.  
The Y-Axis has arbitrary units, represents quantitation by ImageQuant of radioisotopic 
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signals detected by phosphorimager screens as scanned in a Typhoon 9400 FLA laser scanner. 
Error bars represent the standard error multiplied by 2 (Table 3.4.3.2). 
 
B) The chart was created using numerical values from Appendix Table 3.4.3.2. These 
numbers represent the average area and strength of each upper and lower band in the 
basolateral medium samples in Figure 3.4.3.2.B, generated using ImageQuant TL. This graph 
is shows the labeled macromolecules in the SDS-PAGE gels with samples of basolateral 
medium after treatment (or not) with 0.5 µM Doxo, 2.0 µM Doxo, or 4.0 µM CPT. The Y-
Axis has arbitrary units, represents quantitation by ImageQuant of radioisotopic signals 
detected by phosphorimager screens as scanned in a Typhoon 9400 FLA laser scanner. Error 
bars represent the standard error multiplied by 2. (Table 3.4.3.2) 
In accordance with the data obtained for 35S-labeled macromolecules (Figure 3.4.3.1) SDS-
PAGE also indicated a reduction in 35S-labeled macromolecules in the apical and basolateral 
media after incubation with 4.0 µM Doxo (Figure 3.4.3.3). The 4.0 µM CPT treatment had a 
more significant effect than earlier treatments by Doxo. Opposed to the preceding experiment 
(Figure 3.4.2.3), we had no reduction in 35S-labeled macromolecules secreted apically in the 
Doxo treated samples this time (Figure 3.4.3.3). 
 
The lysate samples were more difficult to compare to the previous experiment with Doxo, 
since the two (upper and lower) bands were less separated in this experiment Figure 
3.4.3.3.A: cell lysate compared to Figure 3.4.2.4). Of note is also that the Doxo concentrations 
used are different. 
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4 Discussion 
4.1 DNA damage induced morphological changes in 
the Golgi apparatus structure in MDCK II cells 
The aim of this study was to induce DNA damage and visualize the effect on the morphology 
of the Golgi apparatus, and to analyze the effect on PG sorting and secretion in polarized 
epithelial cells. 
The Golgi apparatus in an MDCK cell grown under optimal growth conditions should form a 
tight monolayer with each cell having a columnar shape, with the Golgi apparatus forming a 
ribbon-like structure located in the apical region, above the nucleus (Bacallao et al. 1989). In 
our visualization experiments this was similarly observed, where optical planes towards the 
basolateral side of columnar epithelial cells, below the nucleus, had little Golgi-specific 
signal. However, in our visualization experiments the cells were grown on glass bottom 
dishes, which are not as optimal for growing a tight cell layer as the filters used in Bacallao et 
al.’s experiments (Bacallao et al. 1989). Thus, the cell layer is not as tight, and the cells 
themselves are not as columnar as they would be when grown on filter. For this reason, in our 
images the Golgi apparatus is not located to the same degree towards the apical side, and is 
located more towards the side of the nucleus in the middle plane. Nucleus size and position 
was visualized using the Hoechst stain. From this area of the cell, the Golgi marker is 
naturally absent. When a DNA inducing agent was added, an x-, y- and z-plane dispersal was 
induced. Areas of the cell cytoplasm that previously had no Golgi signal present, now show a 
less concentrated and dispersed signal.  
In this thesis we worked with DNA damaging agents that have been reported to increase cell 
death due to apoptosis (Liu et al. 2000; Morris & Geller 1996; Tacar, Sriamornsak & Crispin 
R. Dass 2013; Eom et al. 2005). It has also been observed that changes in Golgi morphology 
can occur as a result of apoptosis (Qian & Yang 2009; Chiu et al. 2002; Jung et al. 2006; Lane 
et al. 2002; Mancini et al. 2000). So the changes to Golgi morphology seen in this thesis could 
be wholly or partially a result of apoptosis. However, it has been shown that treatment with an 
anti-apoptotic drug reduced the number of apoptotic cells after treatment with CPT, but 
without causing a reduction in Golgi dispersal (Farber-Katz et al. 2014). This indicates that 
the Golgi dispersal from DNA damage is not linked to the dispersal from apoptosis. 
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Fragmentation and dispersal of the Golgi apparatus can occur in other situations as well. For 
example, treatment with the microtubule depolymerizing agent nocodazole creates a situation 
where the Golgi disperses and locates to specific ER exit sites where the stacks regenerate and 
most Golgi function is restored (Iida & Shibata 1991; Cole et al. 1996). This sets a precedent 
of Golgi function being intact despite morphological changes. However, microtubule 
depolymerized dispersal of the Golgi apparatus is unlike the GOLPH3/MYO18A/F-actin 
pathway in that the fragmentation in this pathway is random, the Golgi apparatus completely 
disperses through the cytoplasm, and does not specifically localize to peripheral sites in the 
cell.  
Another example is during mitosis, where the Golgi apparatus disperses through the 
activation of a MEK1/ERK-signaling cascade (Wei & Seeman 2009). This does not employ 
the same mechanisms as DNA damage induced Golgi dispersal, as cell-cycle arrest in CPT 
treated cells are observed to occur in G1 or early S phase, and the dispersal of the Golgi 
apparatus is noticeable after cell proliferation as recovered (Farber-Katz et al. 2014).  
In future experiments it could be interesting to perform 3D modeling with several z-stacks 
from the same sample and process these through iMaris, in combination with a time-lapse 
experiment, utilizing the lower passage MDCK II PAPST1-GFP cells due to their sensitivity 
to DNA damage. This would allow us to produce a 3D model of Golgi dispersal as it happens 
in individual cells. To reduce the effects of photo-bleaching, the interval between z-stack 
scanning would have to be set significantly higher than what was done in the time-lapse 
experiment in this thesis. Such experiments could yield better dispersal data through iMaris, 
as long as complications like cell death does not compromise the experiment.  
4.2 Cell viability assays 
While doing initial imaging experiments to investigate possible Golgi apparatus dispersal, it 
was discovered that high concentrations of Doxo and CPT would cause a loss of cell layer 
confluency in the 35 mm MatTek glass bottom dishes. Earlier findings have also observed 
apoptosis mediated cell death through treatment with both CPT (e.g. Liu et al. 2000; Morris & 
Geller 1996) and Doxo (e.g. Tacar, Sriamornsak & Crispin R. Dass 2013; Eom et al. 2005). 
This led us to investigate the viability of cells treated with DNA damaging agents. The 
activation of the GOLPH3/MYO18A/F-actin pathway triggered by such agents should protect 
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against activation of apoptosis and increase cell survival (Farber-Katz et al. 2014), but it has 
also been reported that both CPT and Doxo have cytotoxic properties beyond damage to DNA 
(Liu et al. 2000; Tacar, Sriamornsak & Crispin R Dass 2013; Farber-Katz et al. 2014). For 
this reason, it is difficult to say whether any cell death observed has a single cause.  
 
What was interesting was that MDCK II cells treated with Doxo frequently showed loss of 
cell layer confluency when treated with more than 3 μM Doxo during visualization 
experiments (mentioned in Section 3.2: Incubation with DNA damaging agents), but the 
Trypan blue exclusion assays showed at least 90 % viability after incubation in the presence 
of 5 μM Doxo or less (Section 3.3.2: Trypan blue viability assay), without any significant 
reduction in total cell number due to loss of cell adhesion. Incubation with CPT showed a 
significant decline in total cell numbers compared to control at concentrations higher than 4 
μM, indicating reduced cell adhesion as well as possible cell death. This is important, because 
a consequence of a high viability loss, or a reduction in cell number, results in a reduction in 
the total synthesis of PGs in a culture system.  
4.3 Metabolic 35S-labeling of PGs 
A major aim of this thesis was to investigate to what extent a dispersed Golgi apparatus was 
functionally affected. One major function of the Golgi apparatus in mammalian cells is the 
synthesis and secretion of PGs. As discussed in the introduction, there are still areas of Golgi 
function that are unknown, leading to several models for how the organelle operates. It was 
hoped that we could expand our understanding of the Golgi apparatus by addressing how the 
Golgi functions like synthesis, sorting, and secretion of PGs are affected when the organelle 
system is in a dispersed state. If normal Golgi functions is retained it could operate with or 
without a reduction in efficiency. Glycosylation mechanisms could be performed as normal, 
or there could be possible changes to the glycosylation patterns. GAG composition could 
change, as well as the length, type and sulphation patterns of the individual GAGs. There 
could be a change in polarized sorting in epithelial cells, and these changes could be 
connected to certain morphological changes in the Golgi apparatus. 
The labeling experiments we performed showed us that the Golgi apparatus appears to have 
retained some function post-death. We still found sulphated PGs secreted to the apical and 
basolateral media. We did not, however, see any major change in the sorting and secretion of 
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PGs between apical and basolateral media. In experiment 3.4.2 we observed a reduction in 
apical and basolateral sorted PGs (Figure 3.4.2.3), but a potential increase in PGs in the cell 
fraction (Figure 3.4.2.4). This could be an indication of an increase in the time lag between 
synthesis and secretion of PGs. In the final experiment (Section 3.4.3: Effect of doxorubicin 
synthesis and sorting) we were able to observe a reduction in sulphated PGs in the cell lysate 
and both apical and basolateral media when the cells were treated with 4.0 μM CPT (Figure 
3.4.3.3). We also observed a reduction of sulphated PGs in lysates and basolateral medium 
samples from cells treated with 2.0 μM Doxo, but not in the apical medium samples.  
Due to the large reduction of 35S-labeled macromolecules in the cell lysate and in the apical 
and basolateral media after incubation with 4.0 μM CPT, there is a good possibility that this is 
a result of loss of cell adhesion and/or cell death. However, our cell viability assays (Section 
3.3: Cell viability) and microscope visualization (Section 3.2: Incubation with DNA 
damaging agents) indicated that this was not the case. Due to the low number of experiments 
performed, it is difficult to conclude, and the viability criteria need to be established firmly. 
Especially considering that in one experiment, treatment of cells with 2.0 μM Doxo gives no 
significant reduction in apical secretion of PGs as observed by SDS-PAGE analysis (Figure  
3.4.3.3), while another experiment shows a significant reduction in apically secreted PGs after 
SDS-PAGE for cells treated with 0.75 μM Doxo (Figure 3.4.2.3). In conclusion, there seems 
to be a reduction in the synthesis of 35S-sulphate labeled macromolecules upon Doxo 
treatment, but the concentration dependence needs to be addressed further. 
Additional experiments could be performed to investigate whether there is a variation in the 
change of modification pattern and synthesis levels for individual PGs that are being secreted 
or remain in the cell fraction. It could be interesting to analyze if the sorting of PGs rich in CS 
or HS are affected similarly post Golgi dispersal. It could also be of interest to analyze the PG 
sulphation patterns in cells with a dispersed Golgi apparatus. More metabolic labeling 
experiments could be performed to better quantify the reduction in PG secretion to strengthen 
the data obtained, and to investigate whether the reduction is similar for both apical and 
basolateral secretion of CS- and HSPGs. Considering there are also secretory Golgi apparatus 
bypass routes described for MDCK cells (Tveit et al. 2009; Prydz et al. 2013). It could also be 
worth labeling the cells with 35S-cysteine/methionine to detect changes in overall protein 
synthesis and secretion after Golgi dispersal by Doxo or CPT. 
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Incubation of MDCK cells with Brefeldin A (BFA), which in most cell types causes a 
disassembly of the Golgi complex  by preventing COPI vesicles to bind to Golgi membranes 
by inhibition of ARF1 (Fujiwara et al. 1988; Alvarez & Sztul 1999; Orci et al. 1991; 
Donaldson et al. 1992), have shown that treatment of the more BFA-resistant MDCK cells 
with high concentrations of BFA causes a retardation of secreted proteins, particularly in the 
apical direction, and an accumulation in the ER and ERGIC, giving a more dispersed 
distribution of molecules that normally enter the Golgi apparatus (Tveit et al. 2009). This 
could be similar to what was observed in this thesis in section 3.4.2, and might warrant further 
investigation in the future.  
 
It has also been observed that the transport retardation of secreted proteins is BFA 
concentration dependent in MDCK cells. At low concentrations (2 μg/mL) only apical 
transport is affected, while basolateral transport is only affected at higher concentration (5 
μg/mL and above) (Tveit et al. 2009). It is possible that PG synthesis and sorting after 
dispersal of the Golgi complex due to DNA damage induction could be concentration 
dependent in a similar manner. We observed some variations in concentration which could be 
attributed to this, with a small increase in basolaterally secreted macromolecules at 0.5 µM 
Doxo but a reduction at 0.75 µM Doxo (Figure 3.4.2.3). However, we would need to do more 
experiments at these concentrations to establish the result as significant, especially since this 
was not reproduced in the last experiment (Figure 3.4.3.2). 
  
It has also been shown that in the case of apical secretory transport of Serglycin-GFP that 
bypasses the Golgi apparatus, that these protein cores were secreted without Golgi 
modifications, with a lower molecular mass. Since these protein cores lack sulphate labeling, 
it was not possible to establish whether we have an increase in secretion of unmodified 
proteins, and this could be worth investigating in the future.  
4.4 Golgi morphology changes in cancer 
development and GOLPH3 
As stated in the introduction, changes in the Golgi apparatus structure and internal 
environment have been observed in cancer cells (Kellokumpu et al. 2002; Li & Wang 1989; 
Schulenberg et al. 2003). Further, altered glycosylation in cancer cells is prolific and possibly 
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universal (Gao et al. 2012), warranting further investigations into how tumor cells change 
their glycosylation patterns, both as studies of how this affects cell survival, but also for 
developing novel screening methods for certain cancers (Dabelsteen 1996). These alterations 
could change antigenicity (Peracaula et al. 2003; Bresalier et al. 1996; Burke et al. 2006; 
Garbar et al. 2008; Tabarés et al. 2006), which could aid cancer cells in avoiding immune 
system surveillance. Glycans are further involved in tumor cell processes like cell signaling, 
tumor cell dissociation and invasion, cell–matrix interactions, tumor angiogenesis, and 
metastasis (Pinho & Reis 2015). 
 
It would be of interest to investigate whether the changes in Golgi morphology due to 
incubation with DNA damage inducers observed in this thesis, share similarities with changes 
in the Golgi morphology and proteoglycan synthesis and cell surface transport observed in 
cancer cells (Salanti et al. 2015). Visually, the morphological changes to the cancer cells are 
very similar to pH dependent dispersal of the Golgi apparatus, where in both cases the Golgi 
apparatus can be relatively well dispersed through the cytoplasm of the whole cell 
(Kellokumpu et al. 2002).  Since it has been shown that GOLPH3 is an oncogene that when 
overexpressed is associated with poor clinical outcome in several cancer types (Hu et al. 
2013; Hua et al. 2012; Kunigou et al. 2011; Li et al. 2012), and overexpression of GOLPH3 
leads to Golgi dispersal (Ng et al. 2013), more research is required to investigate why 
dispersal of the Golgi apparatus is the cellular response to chemically induced DNA damage.   
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Appendix 1: Materials and reagents 
Radioactive isotopes Manufacturer Cat. No 
[35S] Sulphuric acid 
Hartmann 
Analytic S-RA-1 
   
   Disposable equipment Manufacturer 
 10 mL syringe BD 
 15 mL tubes Sarstedt 
 50 mL tubes Sarstedt 
 6 well culture plate Costar 
 Criterion XT Precast Gel 4 - 12 % Bis - Tris BioRad 
 Cryogenic vial Corning 
 Microfuge tube Sarstedt 
 Sterile 5, 10 and 25 mL pipettes Sarstedt 
 Ultra clear centrifuge tubes Beckman 
 
Nunc EasyFlask 75 cm2 
Thermo 
Scientific 
 35 mm glass bottom dishes MatTek 
 
   
   Equipment Manufacturer 
 Autoclave SS -325 TOMY 
 Cell incubator   
 Centrifuge 5415R Eppendorf 
 Centrifuge GS-15R Beckman 
 Minispin Eppendorf 
 Confocal laser scanning microscope FLUOVIEW 
FV1000  Olympus 
 Liquid scintillation analyzer 1900 TR Packard 
 pH meter 420 Thermo 
 
Typhoon 9400 Variable Mode Imager 
GE 
Healthcare 
 Gel electrophoresis chamber VWR 
 PowerPac basic power supply BIO-RAD 
 
   
   Reagents Manufacturer Cat. No 
DMEM 4.5 g/L glucose w/ L-glutamine  Lonza 
BE12-
604F/12 
DMEM Opti-MEM (1X) Gibco 11058-021 
DMEM RPMI 1640 medium Gibco 
041-90985 
M 
Penicillin-Streptomycin Lonza 17-602 
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Trypsin-EDTA Gibco 25300-104 
Amplify 
GE 
Healthcare NAMP100 
XT-MOPS running buffer BioRad 161-0788 
XT reducing agent BioRad 161-0792 
XT sample buffer BioRad 161-0791 
Protein molecular weight marker [methyl - 14 C] 
methylated Perkin Elmer 81101 UC 
Sephadex G-50 Fine 
GE 
Healthcare 
17-0042-
01 
Camptothecin 
Sigma-
Aldrich C911 
Doxorubicin hydrochloride 
Sigma-
Aldrich D4583 
Dimethylsulfoxide Duchefa  
D1370 
0250 
Ultima Gold XR PerkinElmer 6013119 
   
   Molecular markers and stains  Manufacturer  Cat. No. 
CellLight Golgi-RFP ThermoFisher C10593 
Hoechst 33258 ThermoFisher 31716W 
Propidium iodide ThermoFisher P3566 
BODIPY® TR Ceramide complexed to BSA ThermoFisher B-34400 
Trypan blue stain ThermoFisher T10282 
 
Software Manufacturer Link: 
ImageQuant TL GE Healthcare tinyurl.com/ogptvbh 
iMaris BITPLANE tinyurl.com/p9f9j66 
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Appendix 2: Results data 
Section 3.2: Incubation with DNA damaging agents and changes in the Golgi apparatus 
morphology 
 
Table 3.2.7.1: Golgi apparatus and nuclear areas (µm2) derived from 3D images. 
  Control 0.5 µM 2 µM 
Nuclear area (µm2) 25353 19473 18397 
Nuclear count 82 80 84 
Avg. nuclear area (µm2) 309,1829 243,4125 219,0119 
Golgi area (µm2) 14951 9173,73 34822,45 
Golgi area nuclear average (µm2) 182,3293 114,6716 414,553 
Golgi area relative to nucleus 0,589713 0,4711 1,892833 
‘Nuclear Area’ is the total of nuclear signal (Hoechst) detected in µm2. ‘Nuclear count’ is the number of detected 
nuclei. Avg. Nuclear area is the total nuclear area divided by the number of nuclei, showing the average size of 
the nuclei. ‘Golgi area’ is the total area of Golgi apparatus signal (PAPST1-GFP) detected in µm2. ‘Golgi area 
nuclear average’ is the average Golgi apparatus area per nucleus. ‘Golgi area relative to nucleus’ is the ‘Golgi 
area nuclear average’ divided by the ‘avg. nuclear area’.  
 
Section 3.3: Cell viability after incubation with DNA damage inducers 
Table 3.3.1: Trypan blue, raw data for Doxo. 
  
Contro
l Control 
 
Control 0,4 uM 
0,5 uM 
DOX 
0,75 
uM 
1.0 
μM 
1.0 
μM 
2.0 
μM 
2.0 
μM 
4.0 
μM 
5.0 
μM 
Total 8E+05 1E+06 
 
1E+06 1E+06 1E+06 
2E+0
6 
1E+0
6 
1E+0
6 
1E+0
6 
2E+0
6 
2E+0
6 
1E+0
6 
Alive 7E+05 1E+06 
 
1E+06 1E+06 9E+05 
2E+0
6 
1E+0
6 
1E+0
6 
1E+0
6 
2E+0
6 
1E+0
6 
9E+0
5 
Dead 20000 40000 
 
40000 100000 50000 90000 30000 50000 
1E+0
5 70000 90000 70000 
Viability 0,97 0,97 
 
0,97 0,93 0,95 0,95 0,98 0,96 0,91 0,96 0,98 0,93 
 
Table 3.3.2: Trypan blue, avgerage data for Doxo. 
This table has the average data of values from table 3.3.1 where applicable. 
  Control 0.4 μM 
 
0.5 μM 
0,75 
μM 1.0 μM 
2.0 
μM 
4.0 
μM 
5.0 
μM 
    
Avg. Total 1E+06 1E+06 
 
1E+06 2E+06 1E+06 1E+06 2E+06 1E+06 
    
Avg. Alive 1E+06 1E+06 
 
9E+05 2E+06 1E+06 1E+06 1E+06 9E+05 
    
Avg. Dead 33333 1E+05 
 
50000 90000 40000 85000 90000 70000 
    Avg. 
Viability 0,97 0,93 
 
0,95 0,95 0,97 0,935 0,98 0,93 
    Avg. 
Relative 1 1,234 
 
0,921 1,519 1,092 1,329 1,424 0,94 
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Table 3.3.3: Trypan blue, raw data for CPT. 
  
Contro
l Control 
 
Control 2.0 μM 2.0 μM 
2.0 
μM 
4.0 
μM 
4.0 
μM 
5.0 
μM 
6.0 
μM 
6.0 
μM 
10.0 
μM 
Total 2E+06 2E+06 
 
1E+06 1E+06 1E+06 
1E+0
6 
2E+0
6 
9E+0
5 
4E+0
5 
2E+0
6 
3E+0
5 
2E+0
5 
Alive 2E+06 1E+06 
 
1E+06 910000 1E+06 
1E+0
6 
1E+0
6 
8E+0
5 
3E+0
5 
2E+0
6 
3E+0
5 90000 
Dead 40000 70000 
 
40000 140000 1E+05 50000 70000 80000 80000 
1E+0
5 60000 60000 
Viability 0,98 0,96 
 
0,97 0,87 0,89 0,97 0,95 0,91 0,81 0,93 0,84 0,6 
 
Table 3.3.4: Trypan blue, average data for CPT. 
This table has the average data of values from 3.3.3 where applicable. 
  Control 2.0 μM 
 
4.0 μM 5.0 μM 6.0 μM 
10.0 
μM 
      
Avg. Total 2E+06 1E+06 
 
1E+06 420000 1E+06 2E+05 
      
Avg. Alive 1E+06 1E+06 
 
1E+06 340000 9E+05 90000 
      
Avg. Dead 50000 1E+05 
 
75000 80000 90000 60000 
      Avg. 
Viability 0,97 0,88 
 
0,93 0,81 0,885 0,6 
      
Avg.Relative 1 0,702 
 
0,756 0,2681 0,651 0,096 
       
 
 
Section 3.4: Incubation with DNA damaging agents and changes in the Golgi apparatus 
morphology. 
Table 3.4.1.1: Scintillation counts of Incorporation 35S-sulphate into macromolecules by MDCK II cells 
and MDCK II Serglycin-GFP cells treated or not with 2.0 µM CPT for 4 and 24 h. 
  Basolateral     Apical     Lysate   
MDCKII Count Type MDCKII Count Type MDCKII Count Type 
1. 133363 Control 1. 39735 Control 1. 15925 Control 
2. 69754 Control 2. 32309 Control 2. 9498 Control 
3. 64639 2uM CPT, 4H 3. 34612 2uM CPT, 4H 3. 8574 2uM CPT, 4H 
4. 159948 2uM CPT, 4H 4. 30989 2uM CPT, 4H 4. 7987 2uM CPT, 4H 
5. 68299 
2uM CPT, 
24H 5. 49288 
2uM CPT, 
24H 5. 10558 
2uM CPT, 
24H 
6. 115001 
2uM CPT, 
24H 6. 76242 
2uM CPT, 
24H 6. 10262 
2uM CPT, 
24H 
Avg 
Controll 101559   
Avg 
Controll 36022   
Avg 
Controll 12712   
Avg 4h 112294   Avg 4h 32801   Avg 4h 8281   
Avg 24h 91650   Avg 24h 62765   Avg 24h 10410   
Stdev. Ctrl 31804,5   Stdev. Ctrl 3713   Stdev. Ctrl 3214   
Stdev. 4H 47654,5   Stdev. 4H 1812   Stdev. 4H 293,5   
Stdev. 24H 23351   Stdev. 24H 13477   Stdev. 24H 148   
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  Basolateral     Apical     Lysate   
MDCKII-
SG Count Type 
MDCKII-
SG Count Type 
MDCKII-
SG Count Type 
1. 72943 Control 1. 22089 Control 1. 10997 Control 
2. 69104 Control 2. 39193 Control 2. 21803 Control 
3. 144786 2uM CPT, 4H 3. 39500 2uM CPT, 4H 3. 14615 2uM CPT, 4H 
4. 79193 2uM CPT, 4H 4. 33573 2uM CPT, 4H 4. 22453 2uM CPT, 4H 
5. 64056 
2uM CPT, 
24H 5. 34551 
2uM CPT, 
24H 5. 16462 
2uM CPT, 
24H 
6. 57649 
2uM CPT, 
24H 6. 60210 
2uM CPT, 
24H 6. 13995 
2uM CPT, 
24H 
Avg 
Controll 71023,5   
Avg 
Controll 30641   
Avg 
Controll 16400   
Avg 4h 111990   Avg 4h 36537   Avg 4h 18534   
Avg 24h 60852,5   Avg 24h 47381   Avg 24h 15229   
Stdev. Ctrl 1919,5   Stdev. Ctrl 8552   Stdev. Ctrl 5403   
Stdev. 4H 32796,5   Stdev. 4H 2964   Stdev. 4H 3919   
Stdev. 24H 3203,5   Stdev. 24H 12830   Stdev. 24H 1234   
 
Table 3.4.2.1: Scintillation count of MDCK II PAPST1-GFP treated with 0.25 µM, 0.5 µM or 0.75 µM 
Doxo. 
  Apical Basolateral Lysate 
MDCKII Count Count Count 
Control 13476 34794 52655 
Control 14570 30770 37430 
Control 13805 28109 44888 
250nM 13633 27341 43268 
250nM 12486 29667 24936 
250nM 14295 27659 43920 
500nM 12429 31027 73754 
500nM 10155 42497 51361 
500nM 12033 36953 56135 
750nM   27771 55358 
750nM 10060 31731 48706 
750nM 11751 26447 47957 
Avg. Control 13950,33333 31224,33333 44991 
Avg. 250nM 13471,33333 28222,33333 37374,66667 
Avg. 500nM 11539 36825,66667 60416,66667 
Avg. 750nM 10905,5 28649,66667 50673,66667 
Std. error. Ctrl 324,0629226 1943,117798 4395,380643 
Std. error. 250 528,4323777 728,1431483 6222,180682 
Std. error. 500 701,3786424 3311,715836 6809,579388 
Std. error. 750 690,3478592 1587,367352 2352,125587 
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Table 3.4.2.3: SDS-PAGE signal bands of MDCK II PAPST1-GFP treated with 0.25 µM, 0.5 µM or 0.75 
µM Doxo. 
  Apical Basolateral Lysate Lysate 
MDCK II 
PAPST1-GFP Volume Volume 
Top Band 
Volume 
Middle Band 
Volume 
Control 1359508 3946367 1208394 3000922 
Control 1471742 3161074 1224623 2552187 
Control 1439152 2863232 1609393 2845466 
250 1624086 2766414 2125270 3597282 
250 1531120 2589881 923724 1440071 
250 1664879 3286051 1877695 2657652 
500 1291006 3369924 4897226 4453219 
500 1371574 3863581 2278311 2742204 
500 1099666 3222758 3745082 4760059 
750   2878330 3479055 3082264 
750 768840 2562019 3049296 3006106 
750 905930 2475731 3208275 2754463 
Avg. Ctrl. 1423467,33 3323557,67 1347470 2799525 
Avg. 250nM 1606695 2880782 1642229,667 2565001,667 
Avg. 500nM 1254082 3485421 3640206,333 3985160,667 
Avg. 750nM 837385 2638693,33 3245542 2947611 
Std. error Ctrl 33334,788 323056,271 131045,2702 131559,5007 
Std. error 250nM 39579,8883 208944,328 366292,7517 624453,8648 
Std. error 500nM 80635,0347 193793,874 757832,0226 627758,8849 
Std. Error 750nM 55966,7581 122380,151 125452,2771 99044,80917 
  
Table: 3.4.3.1: Scintillation count of MDCK II PAPST1-GFP treated with 0.5 µM and 2.0 µM of Doxo, 
and 4.0 µM CPT. 
  Lysate Apical Basolateral 
MDCK II PAPST1-
GFP Count Count Count 
Controll 10618 10657 14376 
Controll 10134 10619 14765 
Controll 10011 9990 12532 
0.5 µM Doxo 10280 10914 13674 
0.5uM Doxo 11283 10606 15173 
2 µM Doxo 9418 7669 11113 
2uM Doxo 8758 6761 9783 
2uM Doxo 9381 7867 9848 
4uM CPT 5786 6275 5922 
4uM CPT 6038 6758 6782 
4uM CPT 5186 5800 6172 
Avg. Ctrl. 10254,33333 10422 13891 
Avg. 0.5uM Dox 10781,5 10760 14423,5 
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Avg. 2uM Dox 9185,666667 7432,333333 10248 
Avg. 4uM CPT 5670 6277,666667 6292 
Std. error Ctrl 185,2676742 216,27837 688,716439 
Std. error 0.5uM 
Doxo 501,5 154 749,5 
Std. error 2uM Doxo 214,0999247 340,4983276 432,9068414 
Std. error 4uM CPT 252,6974476 276,5539931 255,4081701 
  
Table 3.4.3.2: SDS-PAGE of MDCK II PAPST1-GFP treated with 0.5 µM and 2.0 µM of Doxo, and 4.0 
µM CPT. 
  Apical Basolateral Lysate 
MDCK II PAPST1-
GFP Volume Volume Volume 
Control 681928 11734199 1964184 
Control 716941 12887543 2317056 
Control 789004 12548146 2430093 
500nM Doxo 729045 13396534 1664494 
500nM Doxo 792907 11402490 1938796 
2.0uM Doxo 708094 9565515 1747278 
2.0uM Doxo 775422 9596049 1525402 
2.0uM Doxo 822121 11027229 1736976 
4.0uM CPT 278744 3447084 156641 
4.0uM CPT 346611 2865862 223462 
4.0uM CPT 351354 3534413 202374 
Avg. Ctrl. 729291 12389962,7 2237111 
Avg. 500nM  Doxo 760976 12399512 1801645 
Avg. 2.0uM Doxo 768545,6667 10062931 1669885,33 
Avg. 4.0uM CPT 325569,6667 3282453 194159 
Std. error Ctrl 31520,94182 342207,087 140310,609 
Std. error 500nM 31931 997022 137151 
Std. error 2uM 33095,83132 482229,564 72302,8538 
Std. error 4uM CPT 23452,83427 209815,502 19722,0366 
 
 
 
 
